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Abstract 
 
Outcomes and Expenditures of Clostridium Difficile Infection in 
Pediatric Solid Organ Transplant Recipients 
 
 
You-Li Ling, M.S. Phr. 
The University of Texas at Austin, 2014 
 
Supervisor: Karen L. Rascati 
 
 
 The main purpose of this study was to assess outcomes (i.e., inpatient 
mortality, transplant failure or rejection, colectomy, and hospital length of stay) of 
clostridium difficile infection (CDI) and the association of expenditures (i.e., charges 
and costs) and CDI in pediatric solid organ transplant (SOT) recipients. Data from the 
2000, 2003, 2006, and 2009 Kids’ Inpatient Database (KID) files were used to 
identify events with SOT- related ICD-9-CM diagnosis codes.  
Logistic regression was used to assess the association of CDI and dichotomous 
outcome variables, while log-linked gamma regression models were used to assess the 
association of CDI and continuous outcome variables. Methods accounting for the 
complex survey sample design of the KID were used when performing all statistical 
analyses.  
The total number of pediatric SOT hospital events was 48,286. The overall 
prevalence of CDI for pediatric SOT hospitalizations was 1.76%. For SOT 
hospitalizations with CDI, inpatient mortality was 1.63%; the prevalence of transplant 
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failure or rejection events was 27.71%; the prevalence of a colectomy was 4.86%. The 
median hospital length of stay was seven days; the median charge and cost for each 
hospitalization was $48,409 and $17,412, respectively. The results showed that CDI 
was not significantly associated with inpatient mortality or transplant failure/ rejection 
in pediatric SOT hospitalizations. SOT patients with CDI were 2.6 times more likely 
to have a colectomy than SOT patient without CDI. The mean hospital length of stay 
(LOS) for a SOT admission with CDI was approximately 2 times the mean LOS for a 
SOT admission without CDI. The mean charges and the mean costs for a SOT 
admission with CDI was approximately 2 times that for a SOT admission without 
CDI. 
In conclusion, CDI diagnoses were not significantly associated with higher 
inpatient mortality or transplant failure/ rejection for pediatric SOT hospitalizations. 
But CDI was significantly associated with a higher prevalence of a colectomy, longer 
hospital LOS, higher charges, and higher costs (all p<0.05). To avoid substantially 
higher expenditures and health care utilization, CDI in pediatric SOT recipients 
should be prevented when possible and promptly diagnosed and treated when it 
occurs. 
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Chapter 1: Literature Review 
1.1 Introduction 
Diarrhea is a frequent complication following solid organ transplant (SOT) and 
can cause dehydration, malnutrition, skin breakdown, or even graft loss and death. 
Clostridium difficilie is one of the most concerning bacterial etiologies of diarrhea 
among SOT recipients because SOT recipients are antibiotic users, have vulnerable 
defense mechanisms, and have prolonged hospital stays. The increasing incidence of 
clostridium difficile infection (CDI) in the pediatric population has been reported 
recently. However, little has been reported in the literature regarding costs and 
outcomes in pediatric SOT recipients with CDI. The purpose of this proposed study is 
to evaluate the charges, costs and outcomes of hospitalized pediatric SOT recipients 
with CDI and determine whether CDI is significantly associated with higher charges, 
costs, and worse outcomes using the Kids’ Inpatient Database (KID) from the 
Healthcare Cost and Utilization Project (HCUP).  
 
1.2 Clostridium difficile infections 
Clostridium difficile infection (CDI) accounts for the most common cause of 
antibiotic-associated diarrhea and colitis and annual costs are estimated to be between 
1.1 and 3.2 billion dollars in the United States health care system.1,2 Clostridium 
difficile is a gram-positive, spore-forming anaerobic bacillus and is acquired from the 
environment and spread via the fecal-oral route.3 The process of CDI includes a 
disturbance of the normal gut flora, colonization of a exotoxin-producing strain of 
clostridium difficile, and mucosal damage due to toxin A and toxin B released by 
these bacillus.4 The administration of broad-spectrum antibiotics, such as 
fluoroquinolones, cephalosporins, clindamycin, sulfonamides, tetracyclines, and 
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penicillins, can alter the normal colonic microflora and lead to CDI. CDI commonly 
occurs in hospitals and long-term care facilities.5,6  
 
1.2.1 Clinical Presentation 
The clinical presentation of clostridium difficile infections (CDIs) varies widely 
from asymptomatic intestinal colonization to diarrhea, pseudomembranous colitis, 
colonic perforation, toxic megacolon and death.6,7 Symptoms include diarrhea, low 
abdominal pain and distention, fever, nausea, and dehydration. 7  
 
1.2.2 Treatment 
According to the guidelines for diagnosis, treatment, and prevention of 
clostridium difficile infection, CDI severity is categorized into following four 
categories:  
1. Mild disease: CDI with diarrhea as the only symptom;  
2. Moderate disease: CDI with diarrhea with other moderate symptoms that 
are not included in the severe or the complicated disease;  
3. Severe disease: CDI with serum albumin < 3 g/dl and either of the 
followings: 1) a white blood cell (WBC) count ≧15,000 cells/mm3 or 2) 
abdominal tenderness without criteria of complicated disease; 
4. Complicated disease: CDI with at least one of the following signs of 
symptoms: admission to intensive care unit, hypotension with or without 
required use of vasopressors, fever ≥ 38.5 °C, ileus, or significant 
abdominal distention, mental status changes, WBC ≥ 35,000 cells/mm3 or 
<2,000 cells/mm3, serum lactate levels >2.2 mmol/l, or any evidence of 
end organ failure. 
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Discontinuing the antibiotic that caused the CDI is the first step of treatment. 
Depending on the severity of the CDI, the second step of treatment may include 
medication and/or surgery.8  
Medications:  
Antibiotics used to treat C. difficile include metronidazole, fidaxomicin, and 
vancomycin. Metronidazole is usually used in patients with mild to moderate 
CDI. Fidaxomicin serves as an alternate antibiotic for mild to moderate CDI. For 
moderate to severe CDI and complicated CDI, vancomycin is recommended.8 
Surgery:  
CDI may progress despite appropriate medication therapy. If patients have 
severe pain, organ failure or inflammation of the lining of the abdominal wall, 
the performance of surgery to remove a diseased portion of the intestine may 
improve the outcome.8 
Treatment of recurrent CDI:  
To treat the first recurrence of CDI, the same regimen as that of the initial episode 
may be prescribed. For the second recurrence, a pulsed vancomycin regimen is 
recommended. A fecal microbiota transplant should be considered if the patient 
has more than three recurrences of CDI. 
 
1.2.3 Incidence, prevalence, morbidity, and mortality of CDI 
The epidemiological data have shown a marked increase in the incidence of CDI 
across North America over the past decade.9-13 The rate of hospital discharge cases 
with CDI-associated diseases more than doubled (from about 150,000 to about 
300,000 cases) during the period from 2001 to 2005.14 Moreover, Miller et al. found 
that CDI has replaced methicillin-resistant Staphylococcus aureus as the leading 
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etiology of healthcare facility-associated infections in the southeastern United States 
in 2008.15 In addition, the rate of CDI-related mortality increased from 5.7 per million 
population in 1999 to 23.7 per million in 2004 in the United States.16 Coincidently, 
the recent emergence of a hypervirulent toxigenic bacterial strain of C. difficile—
designated North American pulsed-field gel electrophoresis type 1 (BI/NAP1/027)—
has caused increases in both hospitalizations and mortality rates since 2000.13,17,18 
Special features of this strain include: 16 times more production of toxins A and 23 
times more production of toxin B than other strains, fluoroquinolone resistance, and 
the production of a binary toxin.17,19   
 
1.2.4 Risk factors for Clostridium difficile infections 
Antibiotic use was established as the main factor associated with clostridium 
difficile infections.20,21 Studies have shown that broad-spectrum antimicrobial agents 
are most likely to lead to CDI.22,23 But several studies also indicated that the use of 
fluoroquinolones is a predominant risk factor for CDI.13,24 The risk of CDI also 
increases for patients receiving multiple antibiotic treatments.20 Other risk factors for 
CDI include admission to an intensive care unit, age greater than 65 years, 
immunosuppression, multiple and severe underlying illnesses, placement of a 
nasogastric tube, prolonged hospitalization, a recent surgical procedure, residing in a 
nursing home, sharing a hospital room with a patient having CDI, and gastric acid 
suppression.6,25-28 
 
1.3 Clostridium difficile infections in pediatric populations 
1.3.1 Prevalence 
Several studies have demonstrated an increasing CDI trend in pediatric 
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populations in the last decade. 29-32 In recent surveillance, Clostridium difficile has 
also been recognized as an important prevalent diarrheal pathogen in children.29-33 
Two studies conducted retrospective analyses using national-level databases. The 
study conducted by Kim et al. used the Pediatric Health Information System (PHIS), 
which contains inpatient data from more than 40 not-for-profit, freestanding, tertiary 
care children’s hospitals in the United States.30 A total of 4,895 children with CDI 
from 22 tertiary care pediatric hospitals were included. The study showed a 53% 
increase in the annual incidence of CDI from 2.6 cases/1,000 admissions in 2001 to 
4.0 cases /1,000 admissions in 2006. Zilberberg et al. also revealed a crude 9.0% 
annual increased rate of pediatric CDI-related hospitalization from 7.2 to 12.8 per 
10,000 hospital admissions by exploring the Kids’ Inpatient Database (KID), which 
included data from more than 2,500 hospitals from 22 states in 1997 and from more 
than 3,700 hospitals from 38 states in 2006.29  
 Younger age groups tend to have a higher incidence rate of CDI.29 Zilberberg 
et al. evaluated data from KID and detected that age groups 1-4 years and 5-9 years 
had the highest and second highest prevalence of CDI-related hospitalizations 
(approximately 45 and 35 hospitalizations per 10,000 admissions, respectively) 
compared to age groups <1 year, 10-14 years, and 15-17 years (approximately 32, 27, 
and 19 hospitalizations per 10,000 admissions, respectively). Younger age groups also 
have had higher increasing rates in CDI over time.30 Kim et al. stratified their results 
according to age and found the rates of hospital admissions due to CDI increased 85% 
in children 1-5 years of age, while the group of children aged 15-17 increased 50% 
during the same time period, 2001-2006.  
 As for the neonates and infants younger than 1 year, the trend of CDI is 
unclear. In the PHIS study from 2001 to 2006, Kim et al. found no increasing trend in 
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CDI rates among hospitalized infants.30 In contrast, by evaluating data from the 
National Inpatient Sample database, an increasing trend in infant CDI hospitalization 
prevalence (from 2.8 to 5.1 cases per 10,000 hospitalizations between 2000 and 2005) 
was demonstrated by Zilberberg et al.34 However, since previous research indicated 
that C. difficile was normal common flora and nonpathogenic among infants younger 
than 1 year, true morbidity or asymptomatic carriage cannot be determined.35-43    
 The number of community-acquired pediatric CDI cases also increased in the 
past years. Many of these cases were not exposed to the traditional risk factor of 
recent antimicrobial drugs use.32,44,45 Benson et al. conducted a retrospective cohort 
study at the Children’s National Medical Center in Washington, D.C. and revealed a 
significant increase of pediatric community-acquired CDI cases in the outpatient 
setting. The incidence rate of community-acquired CDI increased by 2.5 fold (from 
1.2 cases per 1,000 visits in 2001 to 2.5 cases per 1,000 visits in 2006); 43% of these 
children with CDI lacked a history of recent antibiotic use. A retrospective cohort 
study conducted by Sandora et al. also showed that 25% of 151 CDI episodes among 
the 199 positive tests in patients with diarrhea were community-acquired and 65% of 
patients with community-acquired CDI did not receive any antibiotics.32 Khanna et al. 
reported that 75% of the CDI cases in their population-based cohort study from 1991 
to 2009 were community-acquired; and 16.3% of these cases had no preceding 
antibiotic exposure.  
 The emergence of a more-virulent epidemic strain known as North American 
Pulsed Field type 1 (BI/NAP1/027) is likely associated with the increasing CDI 
prevalence in the pediatric population. Studies have revealed a 19.4% prevalence of 
the BI/NAP1/027 strain in pediatric patients with CDI, and this strain resulted in 
severe outcomes.
46,47  
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1.3.2 Risk factors for CDI in children 
The use of antibiotics, exposure to C. difficile in healthcare settings, and certain 
co-morbid conditions were associated with CDI in pediatric populations. Alteration of 
intestinal microflora due to antibiotics has been established as an important risk factor 
in adult populations. Similar results have been found in pediatric populations. Sandora 
et al. reported 61% and 15% incidence rates of CDI when children received non-
quinolone and quinolone antibiotics in the previous 4 weeks, respectively. Co-morbid 
conditions significantly associated with CDI include: immunosuppression, 
inflammatory bowel disease, solid tumors, solid organ transplantation, cystic fibrosis, 
and the presence of a gastrostomy or jejunostomy tube.32,48-50 By using national-level 
data, Kim et al. also detected 67% of patients in their study had underlying 
neuromuscular, cardiovascular, respiratory, renal, gastrointestinal, hematologic, 
immunologic, metabolic, malignancy, or congenital disorders.30 
 
1.4 Clostridium difficile infections in solid organ transplant (SOT) 
recipients 
1.4.1 Prevalence in SOT Patients 
Diarrhea is a frequently observed complication following solid organ transplant 
(SOT).51-54 This complication can lead to dehydration, malnutrition, skin breakdown, 
alterations in immunosuppressant levels, or even graft loss and death.53,55-57 The most 
common causes of diarrhea among SOT recipients include gastrointestinal infections 
and adverse effects due to immunosuppressant medications.58,59 In SOT recipients, 
one of the most concerning bacterial etiologies of diarrhea is Clostridium 
difficile.54,60,61 Several studies also revealed a higher incidence of CDI in SOT 
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recipients than in the general population of hospitalized patients.57,62,63 Riddle and 
Dubberke summarized the reported incidence of CDI among different organ recipient 
populations. These included an incidence of 3-7% CDI in liver, 3.5-16% in kidney, 
1.5-7.8% in pancreas-kidney, 9% in intestinal, 15% in heart, and 7-31% in lung 
recipients.62 Studies indicated that the highest incidence of CDI in SOT recipients 
occurs within 3 months after transplantation, but that late-onset CDI could be detected 
from months to years after transplantation.57,64,65  
The most common clinical manifestation of CDI in SOT recipients is diarrhea, 
which occurs in 86-97% of these patients. Other symptoms such as fever (11-67%), 
abdominal pain (7-50%), and intestinal obstruction (up to 23%), had been reported as 
well.65-68  
 
1.4.2 Risk factors for CDI in SOT recipients 
Several studies have established risk factors for CDI in SOT recipients. These 
included advanced age, underlying severe co-morbidities, and immune system 
dysfunction due to receiving monoclonal antibody therapy to prevent chronic 
rejection and hypogammaglobulinemia (low levels of serum immunoglobulin).65,66,68 
The prevalence of hypogammaglobulinemia in lung, heart, and liver transplantation is 
common.69-71 Studies also indicated that the incidence of CDI was five times higher in 
SOT recipients with hypogammaglobulinemia.68 In addition, SOT recipients are at 
higher risk for CDI because of perioperative antibiotic use and prolonged hospital 
stays, which are common risk factors in general populations for CDI. 
 
1.4.3 Outcomes of SOT recipients with CDI  
For SOT patients with CDI, worse outcomes, increased morbidity and more 
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complications were supported by several studies. By using a nationwide database, 
Pant et al. demonstrated that SOT recipients with CDI had significantly higher rates of 
in-hospital mortality (7.4% vs. 2.4%), length of stay in hospital (median 9 days vs. 4 
days), charges (median $53,808 vs. $31,488), and organ complications (38.1% vs. 
33.9%), compared to those SOT recipients without CDI.72 Dallal et al. reviewed 2,334 
hospitalized patients with C. difficile colitis from January 1989 to December 2000 
and found that 13% of SOT recipients with CDI and 8% of immunocompetent 
patients developed fulminant colitis (a severe form of uncomplicated acute colitis). 
Among those patients who received a colectomy, 31% of them were SOT recipients. 
Their study also indicated that lung transplant patients were 46 times more likely to 
have C. difficile colitis than general hospitalized patients.6 Boutros et al. evaluated 
1,331 SOT recipients in one institution. Their research showed that 165 patients out of 
1,331 SOT recipients developed Clostridium difficile-associated diarrhea. Of these 
165 patients, a 15.8% incidence of complicated clostridium difficile colitis was found. 
Compared with previous studies, the rate of complicated clostridium difficile colitis in 
SOT recipients was 2 times higher than the general population.73 However, Gellad et 
al. found no association with worse outcomes (mortality, intensive care unit 
admission, or urgent colectomy) in patients with CDI who had a SOT (N=80) versus 
patients with CDI but did not have a SOT (N=86).74 
 
1.5 Clostridium difficile infections in pediatric solid organ transplant 
recipients 
The increased trend of CDI prevalence among pediatric populations is relatively 
recent; thus, there are only a few studies that report relative incidence and outcomes 
in pediatric SOT recipients with CDI. One study performed a retrospective chart 
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review of a children’s hospital and demonstrated a clostridium difficile colitis 
incidence of 5.4% in pediatric patients with lung transplantation. The overall survival 
rate was 75% among pediatric SOT recipients with CDI.75 Blanche et al. studied 
pediatric renal transplant recipients’ complications, and found that bacterial infection 
is one of the major causes of post-transplant morbidity and CDI was the major 
bacterial infection in pediatric renal transplant recipients≦5 years.76  
 
1.6 Use of the Kids’ Inpatient Database (KID) in Health Outcomes Studies 
The Kids’ Inpatient Database (KID) is part of the Healthcare Cost and Utilization 
Project (HCUP) and the data have been collected every three years since 1997. The 
KID contains information about hospital utilization, outcomes, and charges for the 
hospitalized pediatric population. Several studies have used the KID to analyze 
economic burden of disease, resource utilization patterns, and health outcomes. 
Hasegawa et al. used the KID to examine trends in pediatric asthma hospitalizations, 
in-hospital mortality, mechanical ventilation use, and hospital charges between 2000 and 
2009.77 Kourtis et al. described hospital use patterns of an HIV-infected pediatric 
population using the KID in 2000.78 A study regarding epidemiology, outcomes, and costs 
of invasive aspergillosis in immunocompromised children conducted by Zaoutis et al. 
used the KID in 2000 as well.79 
Several studies have demonstrated that the large sample size from the KID is a 
good resource for making nationwide estimations. Researchers can use this database 
to describe hospitalization use patterns, health outcomes, charges, and cost 
attributable to a particular disease. 
One limitation to the use of this database is that for patients with multiple 
admissions per year, patient-level analysis is not possible because there is no uniform 
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patient identifier. The KID only provides discharge-level records. This means that 
individual patients with multiple hospitalizations in a single year may have multiple 
records in the KID, each under a different ID. Readmissions for individual patients 
cannot be identified. 
 
1.7 Study rationale 
SOT recipients are at higher risk of getting CDI because they have impaired 
defense mechanisms, are antibiotic users, and have prolonged hospital stays. Although 
several studies have shown an increasing CDI prevalence in pediatric populations 
recently, based on our literature search, few studies reported the costs and outcomes in 
pediatric SOT recipients with CDI. There were several studies that reported worse 
outcomes, higher costs, and more severe complications because of CDI in adult SOT 
recipients.6,72,80 However, studies of outcomes in pediatric populations were scarce. 
Since pediatric and adult SOT recipients differ in many aspects— etiology of organ 
failure, complexities of surgery, perioperative antibiotic use, immunologic maturation, 
response to immunosuppressive medications, comorbid conditions, and post-
transplant complications and infections—these factors may result in different 
outcomes, severity in complications, and costs in pediatric SOT recipients with CDI 
as compared to their adult counterparts.81-87 The findings of this study will contribute 
to the literature by providing information on the evaluation of utilization, costs, and 
outcomes in pediatric SOT recipients with CDI. By using the nationwide Kids’ 
Inpatient Database (KID), we can reduce the limitations (e.g., regarding certain types 
of immunosuppression regimens, and reduced generalizability) of using data from a 
single center. This study will also help to identify factors associated with worse 
outcomes, complications, mortality, and higher costs. 
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1.8 Objectives and hypotheses 
The objectives and related hypotheses of this study are: 
1. To describe the demographic characteristics based on hospital admissions of 
pediatric SOT recipients with respect to age, gender, race, median 
household income for patient’s ZIP code, payer type, and comorbid 
condition.  
2. To describe the hospital-related characteristics of pediatric SOT admissions 
with respect to hospital size, geographic regions, teaching status, and type 
(e.g. children’s general or specialty hospital). 
3. To describe CDI prevalence based on hospital admissions among pediatric 
patient with SOT. 
4. To describe the outcomes regarding transplant failure or rejection events, 
hospital mortality, colectomies, and hospital length of stay among pediatric 
SOT patients.  
5. To estimate the charges (the amount that hospitals billed for services) and 
costs (charges multiplied by cost-to-charge ratios) of hospitalizations for 
pediatric patients with SOT.  
6. To determine if the presence of CDI is significantly associated with hospital 
mortality while controlling for other covariates (i.e., demographic 
characteristics, comorbid condition, type of organ transplant, and hospital-
related characteristics). 
H1: There is a significant difference in the likelihood of inpatient 
mortality between pediatric SOT patient with CDI and pediatric SOT 
patients without CDI while controlling for other covariates (i.e., 
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demographic characteristics, comorbid condition, type of organ 
transplant, and hospital-related characteristics).  
7. To determine if the presence of CDI is significantly associated with 
transplant failures or rejections while controlling for other covariates (i.e., 
demographic characteristics, comorbid conditions, type of organ transplant, 
and hospital-related characteristics). 
H2: There is a significant difference in the likelihood of having a 
transplant failure or rejection event during a hospitalization between 
pediatric SOT patients with CDI and pediatric SOT patients without 
CDI while controlling for other covariates (i.e., demographic 
characteristics, comorbid conditions, type of organ transplant, and 
hospital-related characteristics).  
8. To determine if the presence of CDI is significantly associated with having 
a colectomy while controlling for other covariates (i.e., demographic 
characteristics, comorbid conditions, type of organ transplant, and hospital-
related characteristics).    
H3: There is a significant difference in the likelihood of having a 
colectomy during a hospitalization between pediatric SOT patients 
with CDI and pediatric SOT patients without CDI while controlling for 
other covariates (i.e., demographic characteristics, comorbid 
conditions, type of organ transplant, and hospital-related 
characteristics). 
9. To determine if the presence of CDI is significantly associated with hospital 
length of stay (LOS) for pediatric SOT patients while controlling for other 
covariates (i.e., demographic characteristics, comorbid conditions, type of 
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organ transplant, and hospital-related characteristics). 
H4: There is a significant difference in hospital length of stay (LOS) 
between pediatric SOT admissions with CDI and pediatric SOT 
admissions without CDI while controlling for other covariates (i.e., 
demographic characteristics, comorbid conditions, type of organ 
transplant, and hospital-related characteristics).  
10. To determine if the presence of CDI is significantly associated with charges 
(the amount that hospitals billed for services) for SOT hospitalizations 
while controlling for other covariates (i.e., demographic characteristics, 
comorbid conditions, type of organ transplant, and hospital-related 
characteristics). 
H5: There is a significant difference in hospital charges between 
pediatric SOT admissions with CDI and pediatric SOT admissions 
without CDI while controlling for other covariates (i.e., demographic 
characteristics, comorbid conditions, type of organ transplant, and 
hospital-related characteristics). 
11. To determine if the presence of CDI is significantly associated with costs 
(charges multiplied by cost-to-charge ratios) for SOT hospitalizations while 
controlling for other covariates (i.e., demographic characteristics, comorbid 
conditions, type of organ transplant, and hospital-related characteristics). 
H6: There is a significant difference in hospital costs between pediatric 
SOT admissions with CDI and pediatric SOT admissions without CDI 
while controlling for other covariates (i.e., demographic 
characteristics, comorbid conditions, type of organ transplant, and 
hospital-related characteristics). 
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Chapter 2: Methods 
2.1 Study design and data source 
This study was a retrospective database analysis. Discharge-level data was 
extracted from the Kids Inpatient Database (KID) for the years 2000, 2003, 2006, and 
2009. The KID is within the Healthcare Cost and Utilization Project (HCUP), which 
is administered by the Agency for Healthcare Research and Quality (Rockville, MD, 
USA)88. The KID was specifically designed to enable analyses of healthcare 
utilization, access to services, charge information, and outcomes for the inpatient 
pediatric population across the United States. Pediatric discharges are stratified by 
uncomplicated in-hospital birth, complicated in-hospital birth, and all other pediatric 
cases. The discharges are sorted by state, hospital, diagnostic-related group (DRG), 
and a random number within each DRG in order to obtain an accurate representation 
of each hospital’s pediatric admissions. By using systematic random sampling, 80% 
of pediatric hospital admissions and complicated in-hospital births and 10% of 
uncomplicated in-hospital births were selected. The KID contains data from 2,500 to 
4,100 hospitals, and 2 to 3 million pediatric inpatient discharge records per year. Data 
sources were derived from 27 states in 2000, 36 states in 2003, 38 states in 2006, and 
44 states in 2009. Discharge weights were developed using stratum in proportion to 
the number of American Hospital Association (AHA) newborns for newborn 
discharges and in proportion to the total number of non-newborn AHA discharges for 
non-newborn discharges. In order to get accurate national estimates, these discharge 
weights must be used. 
 
2.2 Institutional Review Board Approval 
 An Institutional Review Board (IRB) application was submitted to the 
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University of Texas at Austin IRB Board (IRB protocol number: 2013-09-0045). A waiver 
was obtained from the University of Texas at Austin IRB Board because all data used in 
this study from the KID data set were de-identified. 
 
2.3 Data Set  
Three types of data files were used in this research. Two were from data files in 
the KID: Inpatient Core File and Hospital File. The third data file was the Hospital-
specific Cost-to-Charge Ratio Files, which was from The HCUP Supplemental Files. 
(1) Inpatient Core File: This file contains patient demographics, diagnosis and 
procedure information, hospital length of stay, median household income for the 
patient’s zip code, payment information, and discharge weight; 
(2) Hospital File: This file contains hospital characteristics such as teaching status, 
location, size, children’s general or specialty hospital. The classification of the 
hospital’s teaching status, size, and location are based on the American Hospital 
Association (AHA) Annual Survey of Hospitals. Children’s general or specialty 
hospital is designated according to the information from the National Association of 
Children’s Hospitals and Related Institutions (NACHRI) with the following 
categories: 1) not identified as a children’s hospital, 2) children’s general hospital, 3) 
children’s specialty hospital, and 4) children’s unit in a general hospital; 
(3) Cost-to-Charge Ratio Files: These files are from the HCUP Supplemental Files. 
From charge information, we can get the amount that hospitals billed for services. 
However, charges may differ from actual costs of hospital services or the specific 
amounts that hospital received in payment. In order to convert hospital charges to 
estimated actual costs, the HCUP hospital-specific Cost-to-Charge Ratio Files can be 
used for its corresponding databases. 
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Because the variables required for this study were contained in the three different 
data files above, these various files were combined to get the analytical dataset. Data 
on hospitalization events for pediatric solid organ transplantation patients were 
extracted in the full year Inpatient Core Files. The HCUP hospital identifier 
(HOSPID) was used to link the Inpatient Core Files to the full-year corresponding 
Hospital File. The combination of the Inpatient Core File and the Hospital Files was 
linked to the corresponding full-year Cost-to-Charge Ratio File by using the HCUP 
hospital identifier (HOSPID) again. The combination of the Inpatient Core File, 
Hospital File, and Cost-to-Charge Ratio File formed a single year dataset. The 
combination of these 3 files was performed for the 2003, 2006, and 2009 files. 
However, since the corresponding Cost-to-Charge Ratio Files for the KID database 
were not available in 2000, the combination data file for 2000 was a link of 2 files –
the Inpatient Core File and Hospital File. Therefore, we only included cost data in 
2003, 2006, and 2009. The datasets in 2000, 2003, 2006, and 2009 were stacked to 
obtain the final analytical dataset. The linkage process for various datasets is shown in 
Figure 1. 
Figure 1.1: Linkage method to create final analytic dataset 
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2.4 Study population 
All entries with SOT diagnoses or procedures codes were extracted using 
International Classification of Diseases 9th Revision, Clinical Modification (ICD-9-
CM) codes. These included patients with heart (diagnosis codes: V42.1, 996.83; 
procedure codes: 37.5, 37.51), liver (diagnosis codes:V42.7, 996.82; procedure codes: 
50.5, 50.59), lung (diagnosis codes:V42.6, 996.84; procedure codes: 33.5, 33.50, 
33.51, 33.52), kidney (diagnosis codes:V42.0, 996.81; procedure codes: 55.6, 55.69), 
pancreas (diagnosis codes:V42.83, 996.86; procedure codes: 52.8, 52.80-52.86), and 
intestine (diagnosis codes:V42.84, 996.87; procedure codes: 46.97) transplantation. 
Hospitalization events for children between 1 to 17 years old with an SOT diagnosis 
were eligible for this study. Although some previous studies revealed high rate of 
CDI-related hospitalization with infants younger than 1 year old29,89, several studies 
also reported that clostridium difficile was a normal common flora and nonpathogenic 
among this population and true morbidity or asymptomatic carriage cannot be 
determined. 13,35-43,90,91 Therefore, we excluded the events with infants younger than 1 
year old in our study. 
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2.5 Study variables 
2.5.1 Outcomes of Interest 
(1) In-hospital mortality was a dichotomous categorical variable with “did not die 
during hospitalization (coded 0)” versus “died during hospitalization (coded 1).” This 
value was obtained from Inpatient Core Files in the KID. 
(2) Hospital length of stay (LOS) was a continuous variable, which indicated 
length of days of hospitalization. This information was obtained from Inpatient Core 
Files in the KID. 
(3) Hospitalization charge was a continuous variable, which was the amount that a 
hospital billed for services. This information was obtained from Inpatient Core Files 
in the KID. All hospitalization charges were adjusted to 2009 dollars based on the 
Medical Care Consumer Price Index.92     
(4) Hospitalization cost was a continuous variable and was generated from the 
corresponding KID Cost-to-Charge Ratio Files in the HCUP Supplemental Files. All 
hospitalization costs were adjusted to 2009 dollars based on the Medical Care 
Consumer Price Index.92    
(5) Transplant failure or rejection was operationalized as having a transplant 
failure or rejection event during the hospitalization with any of the following ICD-9-
CM diagnoses codes: 996.81-996.84, 996.86, and 996.87. This dependent variable 
was a dichotomous categorical variable with “no transplant failure or rejection (coded 
0)” versus “a transplant failure or rejection event (coded 1).” This value was 
generated from Inpatient Core Files in the KID. 
(6) Colectomy was operationalized as having any of the following colectomy ICD-
9-CM procedure codes: 45.7, 45.71-45.76, 45.79, and 45.8 during hospitalization. 
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This dependent variable was a dichotomous categorical variable with “no colectomy 
(coded 0)” versus “having a colectomy (coded 1).” This value was generated from 
Inpatient Core Files in the KID. 
 
2.5.2 Independent variables 
Presence of CDI was the primary independent variable in this study. It was a 
dichotomous variable and its operational definition was the occurrence of a diagnosis 
of CDI (ICD-9-CM code 008.45) in any listed hospital diagnosis (Maximum 
diagnoses allowed per hospitalization: 15 diagnoses for 2000, 2003, and 2006 data; 25 
diagnoses for 2009 data). This variable was dichotomous with no diagnosis of CDI 
(coded 0) versus a diagnosis of CDI (coded 1). 
 
2.5.3 Covariates 
2.5.3.1 Patient Characteristics 
(1) Demographic variables: The demographic variables identified in the KID data 
set were: age, gender, race, region, payer type, and median household income for the 
patient’s zip code.  
Age was assigned at the time of admission and was treated as ordinal variable with 
four categories: 1-4 (coded 1), 5-9 (coded 2), 10-14 (coded 3), and 15-17 (coded 4) 
because a previous study reported that age groups 1-4 years and 5-9 years had the 
highest and second highest prevalence of CDI-related hospitalizations (approximately 
45 and 35 hospitalizations per 10,000 admissions, respectively) compared to age 
groups <1 year, 10-14 years, and 15-17 years (approximately 32, 27, and 19 
hospitalizations per 10,000 admissions, respectively).29   
Gender was a dichotomous categorical variable with male (coded 0) versus female 
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(coded 1).  
Race was a categorical variable with following categories: white (coded 1), black 
(coded 2), Hispanic (coded 3), Asian or Pacific Islander, Native American, and other 
(coded 4). 
Payer type was a categorical variable which provided information about the 
expected primary payer. This variable had six categories: Medicare (coded 1), 
Medicaid (coded 2), private insurance—includes Blue Cross, commercial carriers, and 
private HMOs and PPOs (coded 3), self-pay (coded 4), and other (coded 5; includes 
charity funding, treatment as part of special research, medically indigent patient, or 
free care, worker's Compensation, Civilian Health and Medical Program of the 
Uniformed Services (CHAMPUS), Civilian Health and Medical Program of the 
Department of Veterans Affairs (CHAMPVA), Title V, and other government 
programs). 
Household income was an ordinal variable which will provide a quartile 
classification of the estimated median household income for the patient’s ZIP code. 
The 4 categories that indicated ordinal levels of household income were: from the 
poorest (Quartile 1) to the wealthiest (Quartile 4). The classification ranges of these 
quartile values varied by years. Table 2.1 describes the dollar ranges among each 
category by different years. 
Table 2.1 The dollar ranges represented by each categories in each year 
Year Quartile 1 Quartile 2 Quartile 3 Quartile 4 
2000 1 - 24,999 25,000 - 34,999 35,000 - 44,999 45,000+ 
2003 1 - 35,999 36,000 - 44,999 45,000 - 59,999 60,000+ 
2006 1 - 37,999 38,000 - 46,999 47,000 - 61,999 62,000+ 
2009 1 - 39,999 40,000 - 49,999 50,000 - 65,999 66,000+ 
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(2) Comorbid conditions: 
Previous studies have shown that additional medical comorbidities were 
associated with CDI in pediatric population.30-32 The comorbid conditions might lead 
to worse outcomes in SOT recipients.72,93-95 Studies have also shown that comorbid 
conditions could serve as a predictor of healthcare costs.96,97 To determine the 
association between additional comorbid conditions and outcomes of pediatric SOT 
recipients, common infections in pediatric SOT recipients: urinary tract infection 
(UTI), pneumonia, and cytomegalovirus (CMV) were identified.98-106 Since post-
transplant lymphoproliferative disease (PTLD) has been recognized as a common 
post-transplant malignancy, the presence of having PTLD was treated as a covariate 
as well.83 The Charlson Comorbidity Index (Deyo modification) was used as the tool 
to quantify the impact of different comorbidities on overall outcomes, charges, and 
costs. CCI is a common comorbidity adjustment measure based on clinical 
diagnoses.107,108 The index includes 19 comorbid conditions with assigned weighted 
scores.108 Table 2.3 describes the Charlson comorbidity conditions, the ICD-9-CM 
codes categorized in those comorbid conditions, and the corresponding weights. The 
validation of its use in administrative claims databases to predict health outcomes and 
control for confounding factors has been established.97,107,108 Rhee et al. developed 
and validated a multispecialty risk index for pediatric surgical patients to adjust 
comorbidities.109 This comorbidity index had superior mortality prediction than the 
CCI because it was developed specifically for pediatric surgical patients. However, 
since this pediatric surgery-specific index has not been fully tested, further external 
validation is required. Therefore, CCI was selected as the measure to adjust for 
additional comorbid conditions in this study. The followings are the operational 
definitions of specific comorbid condition variables of interest in this study: 
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Urinary tract infection (UTI) was operationalized as the occurrence of a 
hospitalization with a diagnosis of UTI (ICD-9-CM code 590.X) in any listed 
diagnosis. This variable was dichotomous with no diagnosis of UTI (coded 0) versus a 
diagnosis of UTI (coded 1). 
Pneumonia was operationalized as the occurrence of a hospitalization with a 
diagnosis of pneumonia (ICD-9-CM code 480-487) in any listed diagnosis. This 
variable was dichotomous with no diagnosis of pneumonia (coded 0) versus a 
diagnosis of pneumonia (coded 1). 
Cytomegalovirus (CMV) was operationalized as the occurrence of the 
hospitalization with a diagnosis of CMV infection (ICD-9-CM code 078.5) in any 
listed diagnosis. This variable was dichotomous with no diagnosis of CMV infection 
(coded 0) versus a diagnosis of CMV infection (coded 1). 
Post-transplant lymphoproliferative disease (PTLD) was operationalized as 
pediatric SOT recipients who had the occurrence of hospitalization with a probable 
diagnosis of PTLD in any listed diagnosis. Since ICD-9-CM codes of PTLD (238.77) 
was implemented in 2009, we used PTLD ICD-9-CM codes based on the 
classification from the Kasiske et al. study and identification of PTLD from WHO in 
2000, 2003, 2006, and 2009 dataset and ICD-9-CM code of PTLD (238.77) in 2009 
dataset.110,111 All ICD-9-CM codes used to identify PTLD are listed in Table 2.2 This 
variable was dichotomous with no diagnosis of PTLD (coded 0) versus a diagnosis of 
PTLD (coded 1). 
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Table 2.2 International Classification of Diseases 9th Revision, Clinical 
Modification (ICD-9-CM) codes used to identify post-transplant 
lymphoproliferative disorders (PTLD) 
Diagnosis ICD-9 CM Codes 
Malignant neoplasm associated with transplanted organ 199.2 
Reticulosarcoma 200.0X 
Lymphosarcoma 200.1X 
Burkitt’s tumor or lymphoma 200.2X 
Primary central nervous system lymphoma 200.5X 
Anaplastic large cell lymphoma 200.6X 
Large cell lymphoma 200.7X 
Other named lymphoma variants 200.8X 
Hodgkin’s paragranuloma 201.0X 
Hodgkin’s granuloma 201.1X 
Hodgkin’s sarcoma 201.2X 
Lymphocytic-histiocytic predominance 201.4X 
Nodular sclerosis 201.5X 
Mixed cellularity 201.6X 
Lymphocytic depletion 201.7X 
Hodgkin’s disease, unspecified 201.9X 
Nodular lymphoma 202.0X 
Peripheral T-cell lymphoma 202.7X 
Other lymphomas 202.8X 
Other and unspecified malignant neoplasms of lymphoid and 
histiocytic tissue 
202.9X 
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Charlson comorbidity index score (CCI) was treated as a ordinal variable with 
an index score of 0 (coded 1), 1 (coded 2), and ≧2 (coded 3) instead of using CCI as a 
continuous variable because a previous study demonstrated that the majority of 
pediatric patients had a CCI score of between 0 and 2, while only a small portion had 
CCI scores ≧3.112 
Table 2.3 Charlson Comorbidity Index (Deyo modification) with corresponding 
ICD-9-CM codes and weighted scores 
Comorbid Condition ICD-9 CM Codes Charlson Score 
Myocardial Infarction 410 – 410.9 1 
Congestive Heart Failure 428 – 428.9 1 
Peripheral Vascular Disease 433.9, 441 – 441.9, 785.4, V43.4 1 
Cerebrovascular Disease 430 – 438 1 
Dementia 290 – 290.9 1 
Chronic Pulmonary Disease 490 – 496, 500 – 505, 506.4 1 
Rheumatologic Disease 710.0, 710.1, 710.4, 714.0 – 714.2, 
714.81, 725 
1 
Peptic Ulcer Disease 531 – 534.9 1 
Mild Liver Disease 571.2, 571.5, 571.6, 571.4 – 571.49 1 
Diabetes 250 – 250.3, 250.7 1 
Diabetes with Chronic 
Complications 
250.4 – 250.6 2 
Hemiplegia or Paraplegia 344.1, 342 – 342.9 2 
Renal Disease 582 – 582.9, 583 – 583.7, 585, 586, 
588 – 588.9 
2 
Moderate or Severe Liver 
Disease 
572.2 – 572.8 3 
AIDS 042 – 044.9 6 
 
(3) Type of organ transplantation 
Type of organ transplantation was treated as a categorical variable with the following 
categories: heart (ICD-9-CM codes: V42.1, 996.83, 37.5, and 37.51), liver (V42.7, 
996.82, 50.5, and 50.59), lung (V42.6, 996.84, 33.5, 33.50, 33.51, and 33.52), kidney 
(V42.0, 996.81, 55.6, and 55.69), pancreas (V42.83, 996.86, 52.8, and 52.80-52.86), 
intestine (V42.84, 996.87, and 46.97) transplantation. 
 
2.5.3.2 Hospital Characteristics 
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Hospital size was an ordinal variable and was assigned to 3 categories: small, 
medium, and large based on the American Hospital Association (AHA) Annual 
Survey of Hospitals (Small—under 100 beds, medium—100-399 beds, and large—
400+ beds). 
Hospital geographic region was a categorical variable and was assigned to the 
following categories based on the AHA Annual Survey of Hospitals: Northeast, 
Midwest, South, and West. 
Teaching Status was a dichotomous variable and was assigned to non-teaching 
hospital (coded 0) and teaching hospital (coded 1) based on the AHA Annual Survey 
of Hospitals. 
Children’s general or specialty hospital was a categorical variable and was 
assigned to the following categories based on the National Association of Children’s 
Hospitals and Related Institutions (NACHRI): 1) not identified as a children’s 
hospital, 2) children’s general or specialty hospital, and 3) children’s unit in a general 
hospital.  
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2.6 Statistical analyses 
Descriptive statistics were used to summarize patient and hospital characteristics 
of pediatric solid organ transplant admissions, charges, costs, and outcomes. Medians, 
means and standard errors were used to describe continuous variables while 
frequencies and percentages were used to describe categorical variables. Logistic 
regressions were performed to examine factors statistically significantly associated 
with the following dichotomous variables: in-hospital mortality, transplantation 
failure/rejection, and colectomy while controlling for other covariates of interest. 
Gamma regressions with log link were used to determine whether having a diagnosis 
of CDI was statistically significantly related to LOS, hospitalization charges, and 
hospitalization costs while controlling for other covariates of interest. Data 
management was conducted using SAS version 9.3 (SAS Institute Inc, Cary, North 
Carolina). Statistical analyses for the complex sampling design were conducted using 
Stata version 12 (StataCorp LP, College Station, Texas). The priori alpha level of 
statistical significance was set at p<0.05 for all statistical analyses. A summary of the 
statistical tests that were performed to address the objectives and hypotheses is 
presented in Table 2.5. 
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2.7 Sample Size Calculations and Test Assumptions 
Sample size calculations and test assumptions are listed for each type of test.  
 
2.7.1 Logistic regressions 
To address objectives 6, 7, 8, logistic regressions were performed. The following 
assumptions were assessed before conducting the analysis: 1) the dependent variable 
should be a binary variable; 2) independence of observations; 3) adequate responses 
in every given category to avoid unstable parameter estimates and standard 
errors.113,114  
 
Figure 2.1 Logistic regression model 
logit [Ө (x)] = log [ Ө(x) / 1-Ө(x)] = α + β1x1 + β2x2 + …….+ β18x18 
Ө (x) = Probability of worse outcomes  
(When addressing objective 6, Ө (x) = Probability of mortality; when addressing 
objective 7, Ө (x) = Probability of having transplant failure or rejection; when 
addressing objective 8, Ө (x) = Probability of colectomy) 
1-Ө(x) = Probability of no worse outcomes  
α = Constant of equation  
β = Regression coefficient of the predictor variables  
X1= Presence of CDI  
X2= Age  
X3= Gender 
X4= Race  
X5= Payer type  
X6= Household income 
X7= UTI  
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X8= Pneumonia  
X9= CMV  
X10= PTLD 
X11= CCI 
X12= Transplant type 
X13= Hospital size 
X14= Hospital geographic region 
X15= Teaching status 
X16= Children’s general or specialty hospital 
For the sample size calculations of logistic regressions, an alpha level of 0.05, 
power of 0.80, and a medium value of the expected squared multiple correlation 
coefficient between independent variable of interest and all other covariates (R2 other 
X=0.032) were assumed.115 The literature has limited information regarding the odds 
ratio and probability of event among mortality, transplant failure or rejection, and 
colectomy in pediatric SOT recipients. However, the research conducted by Pant et al. 
provided these parameters in adult SOT recipients. Therefore, we used these 
parameters to make our sample size estimation. G*Power 3.1.5 software was used to 
calculate sample size.  
For logistic regression with in-hospital mortality as the dependent variable, an 
odds ratio of 2.48 and a probability of mortality for the SOT recipient=0.024 were 
used. Therefore, the minimum total sample size of 7,760 was required.  
For the logistic regression assessing having a transplant failure or rejection as the 
dependent variable, the odds ratio of 1.36 and the probability of having a transplant 
failure or rejection for a SOT recipient=0.339 were used. Therefore, the minimum 
total sample size of 11,567 was required.  
For the logistic regression regarding the presence of a colectomy as the 
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dependent variable, an odds ratio of 3.10 and a probability of colectomy for SOT 
recipient=0.003 were used. Therefore, the minimum total sample size of 33,263 was 
required. 
 
2.7.2 Generalized linear model (GLM)—gamma regression with log link 
The distributions among data with continuous values—hospital length of stay 
(LOS), charges, and costs— were highly positive skewed and violated normality 
assumption. GLM with gamma distribution is recommended when dealing with 
heavy-tailed, positive, and continuous data.116 To address objectives 9, 10, and 11, 
gamma regressions with log link were performed. A small portion (2%) of hospital 
length of stay values were zero indicating a length of stay of less than one full day. 
These were recoded as 1 day so that logarithmic calculations could be conducted. The 
following assumptions were assessed before conducting the analysis: 1) independence 
of each observation in dependent variable; 2) correct specification of the variance 
function; 3) correct specification of the dispersion effect; 4) correct specification of 
the link function; 5) correct form for the explanatory variables; and 6) lack of undue 
influence of individual observations.117 The first assumption of GLM- independence 
of each observation in dependent variable- was violated because we used discharge 
level data and a recurrence of CDI of the same patient could not be identified. 
However, since one previous study has shown that recurrence rate for CDI in 
hospitalized pediatric patients was 7.5%, we assumed that our data will be close to 
patient-level data and thus meet the first assumption.118  
 
Figure 2.2 Generalized linear model (GLM)—gamma regression with log link  
log E(Y|X) = a + b1X1 + b2X2 + ……. + b18X18  
E(Y|X) is the expected predicted value  
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(When addressing objective 9, Y = LOS; when addressing objective 10, Y =Charges; 
when addressing objective 11, Y = Costs) 
a = constant of the equation  
b = regression coefficient of the predictor variables 
X1= Presence of CDI  
X2= Age  
X3= Gender 
X4= Race  
X5= Payer type  
X6= Household income 
X7= UTI  
X8= Pneumonia  
X9= CMV  
X10= PTLD 
X11= CCI 
X12= Transplant type 
X13= Hospital size 
X14= Hospital geographic region 
X15= Teaching status 
X16= Children’s general or specialty hospital 
To confirm the correct link function, the Box-Cox tests were conducted. The 
Box-Cox test can be used to find the appropriate transformation.119 The Box-Cox 
transformation is defined by: 
y(λ)={
yλ−1
λ
, if λ ≠ 0
log(y) , if λ = 0
 
For a log link to be appropriate, the value of λ should be approximate zero. The λ 
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values we obtained were -0.21, -0.14, and -0.14 for length of stay in hospital, charges, 
and costs, respectively. 
In order to confirm the appropriate family of GLM, the modified Park Tests were 
conducted. This test assesses the distribution by doing regression of the raw-scale 
squared residuals from the log link on the log of linear predictors while using GLM 
with a log link and gamma distribution.120  
log((y − ŷ)2) = γ0 + γ1(log(ŷ)) + ε 
y=outcome variable 
ŷ=predicted value of outcome variable 
γ0=constant of the equation 
γ1=coefficient 
ε=error term 
The coefficient (γ1) approximate 2 indicates gamma distribution is 
recommended. The coefficient (γ1) were 2.38, 2.25, and 2.31 for length of stay in 
hospital, charges, and costs, respectively. 
Little information regarding sample size calculation for gamma regression with 
log link has been reported. However, the results from Jin and Zhao’s study indicates 
that the required sample size for a gamma distribution with a logarithmic 
transformation will not exceed the required sample size for a normal distribution 
while given a certain power level.121 Therefore, the required sample size for linear 
multiple regression was used to estimate sample size. For the sample size calculation 
of linear multiple regression, a small effect size (f2=0.02) based on conventional 
value, an alpha level of 0.05, and power of 0.80 were assumed.115 G*Power 3.1.5 
software was used to estimate sample size. With 16 independent variables, the 
minimum total sample size of 1,000 was required. 
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The sample sizes required for each statistical analysis are summarized in Table 
2.4. Based on these values, the minimum total sample size for this study was 33,263. 
 
Statistical analysis Dependent variable Required sample size 
Logistic regression  Mortality 7,760 
Logistic regression  Transplant failure or rejection 11,567 
Logistic regression  Colectomy 33,263 
Gamma regression with log link  Length of stay (LOS) 1,000 
Gamma regression with log link Charges 1,000 
Gamma regression with log link Costs 1,000 
 
 
 
 
 
  
Table 2.4 Summary of sample sizes for the statistical analyses 
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2.8 Post-hoc power analyses 
Before conducting this study, the minimum required sample sizes to reach a 
power of 0.8 were estimated based on the results from adult population because 
limited information for pediatric population has been reported. Therefore, post-hoc 
power analyses were performed in order to determine the power with actual sample 
sizes, standard deviations, and odds ratios. Statistical power was calculated using the 
“powercal” procedure designed for power calculations in generalized linear models 
from Stata version 12 packages (StataCorp LP, College Station, Texas).   
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Table 2.5 Summary of the study objectives, hypotheses, variables, and statistical tests 
Objectives Hypothesis Dependent variable Independent variable Statistical test 
1. To describe the demographic characteristics 
based on hospital admissions of the pediatric SOT 
recipients with respect to age, gender, race, median 
household income for patient’s ZIP code, payer 
type, and comorbid condition. 
N/A N/A N/A Descriptive 
statistics  
2. To describe the hospital-related characteristics 
of pediatric SOT admissions with respect to 
hospital size, geographic regions, teaching status, 
and whether it is a children’s general or specialty 
hospital or children’s unit in a general hospital 
based on the National Association of Children’s 
Hospital and Related Institutions (NACHRI). 
N/A N/A N/A Descriptive 
statistics 
3. To describe CDI prevalence based on hospital 
admissions among pediatric patient with SOT. 
N/A N/A N/A Descriptive 
statistics 
4. To describe the outcomes regarding transplant 
failure or rejection events, hospital mortality, 
colectomies, and hospital length of stay among 
pediatric SOT patients. 
N/A N/A N/A Descriptive 
statistics 
5. To estimate the charges (the amount that 
hospitals billed for services) and costs (charges 
multiply cost-to-charge ratios) of hospitalizations 
N/A N/A N/A Descriptive 
statistics 
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for pediatric patients with SOT. 
6. To determine if the presence of CDI is 
significantly associated with hospital mortality 
while controlling for other covariates (i.e., 
demographic characteristics, comorbid conditions, 
type of organ transplant, and hospital-related 
characteristics). 
H1: There is a significant difference in the 
likelihood of inpatient mortality between 
pediatric SOT patient with CDI and 
pediatric SOT patients without CDI while 
controlling for other covariates (i.e., 
demographic characteristics, comorbid 
conditions, type of organ transplant, and 
hospital-related characteristics). 
Hospital mortality 
(categorical) 
Presence of CDI, age, 
gender, race, payer type, 
household income, UTI, 
pneumonia, CMV, CCI, 
type of organ 
transplantation, hospital 
size, hospital 
geographic region, 
teaching status, 
children’s general or 
special hospital 
(categorical) 
Logistic 
regression 
7. To determine if the presence of CDI is 
significantly associated with transplant failures or 
rejections while controlling for other covariates 
(i.e., demographic characteristics, comorbid 
conditions, type of organ transplant, and hospital-
related characteristics). 
 
H2: There is a significant difference in the 
likelihood of having a transplant failure 
or rejection event during a hospitalization 
between pediatric SOT patients with CDI 
and pediatric SOT patients without CDI 
while controlling for other covariates 
(i.e., demographic characteristics, 
comorbid conditions, type of organ 
transplant, and hospital-related 
characteristics).  
Having a transplant 
failure or rejection 
event (categorical) 
Presence of CDI, age, 
gender, race, payer type, 
household income, UTI, 
pneumonia, CMV, CCI, 
type of organ 
transplantation, hospital 
size, hospital 
geographic region, 
teaching status, 
children’s general or 
Logistic 
regression 
Table 2.5 Summary of the study objectives, hypotheses, variables, and statistical tests (cont’d) 
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special hospital 
(categorical) 
8. To determine if the presence of CDI is 
significantly associated with having a colectomy 
while controlling for other covariates (i.e., 
demographic characteristics, comorbid conditions, 
type of organ transplant, and hospital-related 
characteristics). 
H3: There is a significant difference in the 
likelihood of having a colectomy during a 
hospitalization between pediatric SOT 
patients with CDI and pediatric SOT 
patients without CDI while controlling for 
other covariates (i.e., demographic 
characteristics, comorbid conditions, type 
of organ transplant, and hospital-related 
characteristics). 
Having a colectomy 
(categorical) 
Presence of CDI, age, 
gender, race, payer type, 
household income, UTI, 
pneumonia, CMV, CCI, 
type of organ 
transplantation, hospital 
size, hospital 
geographic region, 
teaching status, 
children’s general or 
special hospital 
(categorical) 
Logistic 
regression 
9. To determine if the presence of CDI is 
significantly associated with hospital length of 
stay (LOS) for pediatric SOT patients while 
controlling for other covariates (i.e., demographic 
characteristics, comorbid conditions, type of organ 
transplant, and hospital-related characteristics). 
H4: There is a significant difference in 
hospital length of stay (LOS) between 
pediatric SOT admissions with CDI and 
pediatric SOT admissions without CDI 
while controlling for other covariates 
(i.e., demographic characteristics, 
comorbid conditions, type of organ 
transplant, and hospital-related 
characteristics). 
Hospital LOS 
(continuous) 
Presence of CDI, age, 
gender, race, payer type, 
household income, UTI, 
pneumonia, CMV, CCI, 
type of organ 
transplantation, hospital 
size, hospital 
geographic region, 
teaching status, 
Gamma 
regression 
with log link 
Table 2.5 Summary of the study objectives, hypotheses, variables, and statistical tests (cont’d) 
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children’s general or 
special hospital 
(categorical) 
10. To determine if the presence of CDI is 
significantly associated with charges (the amount 
that hospitals billed for services) for SOT 
hospitalizations while controlling for other 
covariates (i.e., demographic characteristics, 
comorbid conditions, type of organ transplant, and 
hospital-related characteristics). 
 
H5: There is a significant difference in 
hospital charges between pediatric SOT 
admissions with CDI and pediatric SOT 
admissions without CDI while controlling 
for other covariates (i.e., demographic 
characteristics, comorbid conditions, type 
of organ transplant, and hospital-related 
characteristics). 
Hospital charges 
(continuous) 
Presence of CDI, age, 
gender, race, payer type, 
household income, UTI, 
pneumonia, CMV, CCI, 
type of organ 
transplantation, hospital 
size, hospital 
geographic region, 
teaching status, 
children’s general or 
special hospital 
(categorical) 
Gamma 
regression 
with log link 
11. To determine if the presence of CDI is 
significantly associated with costs (charges 
multiply cost-to-charge ratios) for SOT 
hospitalizations while controlling for other 
covariates (i.e., demographic characteristics, 
comorbid conditions, type of organ transplant, and 
hospital-related characteristics). 
 
H6: There is a significant difference in 
hospital costs between pediatric SOT 
admissions with CDI and pediatric SOT 
admissions without CDI while controlling 
for other covariates (i.e., demographic 
characteristics, comorbid conditions, type 
of organ transplant, and hospital-related 
characteristics). 
Hospital costs 
(continuous) 
Presence of CDI, age, 
gender, race, payer type, 
household income, UTI, 
pneumonia, CMV, CCI, 
type of organ 
transplantation, hospital 
size, hospital 
geographic region, 
Gamma 
regression 
with log link 
Table 2.5 Summary of the study objectives, hypotheses, variables, and statistical tests (cont’d) 
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teaching status, 
children’s general or 
special hospital 
(categorical) 
CDI= clostridium difficile infection; SOT= solid organ transplant; LOS= length of stay; UTI= Urinary tract infaction; CMV= cytomegalovirus; PTLD= post-transplant lymphoproliferative 
disease; CCI= Charlson comorbidity index 
Table 2.5 Summary of the study objectives, hypotheses, variables, and statistical tests (cont’d) 
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Chapter 3: Results 
3.1 Chapter overview 
This chapter provides the study results. All results are organized by study 
objectives and associated statistical analyses. Since the weight for each hospital 
discharge is needed to be applied for generating national-level estimates, we used 
weighted data for descriptive and inferential statements unless results from 
unweighted data were specified. 
 
3.2 Case identification 
From 2000 to 2009, the total numbers for unweighted and weighted pediatric 
discharges in KID were 12,039,432 and 29,629,209, respectively. All entries aged 
between 1 to 17 years old with ICD-9-CM diagnoses or procedures codes for SOT 
were identified. The total unweighted sample size was 28,185. The total weighted 
sample size was 48,286. 
 
3.3 Study objectives 
3.3.1 Objective 1 
Objective 1 was to describe the demographic characteristics based on hospital 
admissions of the pediatric SOT recipients with respect to age, gender, race, median 
household income for patient’s ZIP code, payer type, and comorbid condition. A 
description of unweighted and weighted demographic characteristics is presented in 
Table 3.1.  
Among admissions with SOT, around 52% were for male patients and 48% were 
for female patients. The proportions for all age groups (1~4, 5~9, 10~14, and 15~17 
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year old) ranged from approximately 22% to 27%. Patients with SOT were mainly 
whites (44.2%) and the majority of them had private insurance (40.82%). For income 
quartiles, patients fell nearly evenly in the first, second, third, and fourth quartiles 
(23.32%, 25.56%, 25.12%, and 23.44%, respectively). For comorbid condition among 
patients with SOT, nine percent of them had pneumonia during their hospitalization 
and around two percent had CMV, UTI, and PTLD; over 60 percent of the sample had 
a Charlson Comorbidity Index (CCI) score of zero (CCI=0: 62.29%, CCI=1: 11.69%, 
CCI≥2: 26.03%). 
Among admissions with both SOT and CDI, around 54% were male patients and 
47% were female patients. Almost half (46.24%) of the patients were 1~4 years old. 
Patients with both SOT and CDI were mainly whites (45.89%). Medicaid was the 
expected primary payer for approximately 43% of the admissions for patients with 
both SOT and CDI, followed by the private insurance (42.14%). For income quartiles, 
the proportions among patients with both SOT and CDI were as follows: 24.77% in 
0th~25th percentile, 23.36% in 26th~50th percentile, 30.16% in 51th~75th percentile, and 
19.48% in 76th~100th percentile. For comorbid conditions among events for patients 
with both SOT and CDI, 13.26% included pneumonia and around three percent of 
events included a diagnosis for CMV and PTLD; over 65 percent of the sample had 
CCI score zero (CCI=0: 67.37%, CCI=1: 12.32%, CCI≥2: 20.31%). 
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CDI= clostridium difficile infection; SOT= solid organ transplant; UTI= Urinary tract infaction ; CMV= cytomegalovirus; 
PTLD= post-transplant lymphoproliferative disease; CCI= Charlson comorbidity index 
†includes Asian or Pacific Islander, Native American, and other 
‡includes charity funding, treatment as part of special research, medically indigent patient, or free care, worker's Compensation, 
Civilian Health and Medical Program of the Uniformed Services (CHAMPUS), Civilian Health and Medical Program of the 
Department of Veterans Affairs (CHAMPVA), Title V, and other government programs 
 
 
Unweighted Weighted 
Variable SOT only SOT+CDI SOT only SOT+CDI 
         
Total events, n (%) 27,670 (100.00) 515 (100.00) 47,434 (100.00) 852 (100.00) 
          
G nder  Male 14,464 (52.27) 275 (53.40) 24,724 (52.12) 463 (54.34) 
 
Female 13,127 (47.44) 240 (46.60) 22,590 (47.62) 389 (45.66) 
          
Age 1~4 Years old 7,509 (27.14) 240 (46.60) 12,970 (27.34) 394 (46.24) 
 
5~9 Years old 6,211 (22.45) 111 (21.55) 10,639 (22.43) 183 (21.48) 
 
10~14 Years old 7,136 (25.79) 94 (18.25) 12,235 (25.79) 158 (18.54) 
 
15~17 Years old 6,814 (24.63) 70 (13.59) 11,590 (24.43) 117 (13.73) 
          
Race White 11,842 (42.80) 234 (45.44) 20,964 (44.20) 391 (45.89) 
 
Black 3,851 (13.92) 56 (10.87) 6,563 (13.84) 90 (10.56) 
 
Hispanic 5,335 (19.28) 110 (21.36) 8,833 (18.62) 179 (21.01) 
 
Other† 1,885 (6.81) 30 (5.83) 3,082 (6.50) 48 (5.63) 
      
Payer type 
 
    
 
Medicare 4,183 (15.12) 40 (7.77) 7,111 (14.99) 67 (7.86) 
 
Medicaid 10,644 (38.47) 223 (43.30) 17,931 (37.80) 365 (42.84) 
 
Private 11,063 (39.98) 214 (41.55) 19,364 (40.82) 359 (42.14) 
 
Self-pay 276 (1.00) 8 (1.55) 483 (1.02) 13 (1.53) 
 
Other‡ 1,405 (5.07) 30 (5.83) 2,346 (4.95) 48 (5.63) 
      
Income quartiles for ZIP code      
 
 0
th
~25
th
 percentile 6,678 (24.13) 130 (25.24) 11,062 (23.32) 211 (24.77) 
 
26
th
~50
th
 percentile 7,083 (25.60) 119 (23.11) 12,126 (25.56) 199 (23.36) 
 
51
th
~75
th
 percentile 6,814 (24.63) 158 (30.68) 11,914 (25.12) 257 (30.16) 
 
76
th
~100
th
 percentile 6,378 (23.05) 96 (18.64) 11,119 (23.44) 166 (19.48) 
         
Comorbid condition         
 Pneumonia 2,504 (9.05) 70 (13.59) 4,267 (9.00) 113 (13.26) 
 CMV 517 (1.87) 15 (2.91) 904 (1.91) 24 (2.82) 
 UTI 672 (2.43) 10 (1.94) 1,132 (2.39) 16 (1.88) 
 PTLD 398 (1.44) 15 (2.91) 711 (1.50) 25 (2.93) 
 
CCI   0  17,069  (61.69) 348 (67.57)  29,545  (62.29) 574 (67.37) 
 CCI   1  3,274  (11.83) 64 (12.43)  5,543  (11.69) 105 (12.32) 
 
      ≥2  7,327  (26.48) 103 (20.00)  12,346  (26.03) 173 (20.31) 
Table 3.1 Demographic characteristics of patients with SOT and CDI 
 
Table 3.1 Demographic characteristics of patients with SOT and CDI (cont’d) 
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3.3.2 Objective 2 
Objective 2 was to describe the hospital-related characteristics of pediatric SOT 
admissions with respect to hospital size, geographic region, teaching status, and 
children’s general or specialty hospital. A description of unweighted and weighted 
demographic hospital-related characteristics is presented in Table 3.2.  
Among the weighted discharges with SOT, most of the admissions were at large 
size hospitals (53.88%). Around 19% of the admissions with SOT were in hospitals 
located in the Northeast USA, 22% in the Midwest, 33% in the South, and 26% in the 
West. The proportion of pediatric SOT hospitalizations was highest in teaching 
hospitals (89%). 
Among the weighted discharges with both SOT and CDI diagnoses, most of the 
inpatient admissions were at large (48.4%) and teaching (89.8%) hospitals. Around 
15% of the SOT with CDI admissions occurred in hospitals located in the Northeast 
USA, 22% in the Midwest, 30% in the South, and 32% in the West.  
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CDI= clostridium difficile infection; SOT= solid organ transplant 
 
 
Unweighted Weighted 
Variable SOT only SOT+CDI SOT only SOT+CDI 
Total admissions, n (%) 27,670 (100.00) 515 (100.00) 47,434 (100.00) 852 (100.00) 
Hospital size, n (%) 
        
 
Small 3,167 (11.45) 56 (10.87) 6,156 (12.98) 105 (12.31) 
 
Medium  6,929 (25.04) 154 (29.90) 12,711 (26.80) 275 (32.33) 
 
Large 15,751 (56.92) 268 (52.04) 25,558 (53.88) 412 (48.38) 
Hospital region, n (%) 
 
  
 
  
 
  
 
  
 
Northeast 5,229 (18.90) 74 (14.37) 8,995 (18.96) 128 (15.02) 
 
Midwest 5,604 (20.25) 119 (23.11) 10,243 (21.59) 191 (22.41) 
 
South 9,175 (33.16) 154 (29.90) 15,707 (33.11) 259 (30.45) 
 
West 7,662 (27.69) 168 (32.62) 12,489 (26.33) 274 (32.11) 
Teaching hospital, n (%) 24,649 (89.08) 464 (90.10) 42,418 (89.43) 766 (89.85) 
Children's general or specialty hospital, n (%) 
 
  
 
  
 
  
 
  
 
Not identified as children's hospital 2,424 (8.76) 28 (5.44) 3,959 (8.35) 48 (5.62) 
 
Children's general or specialty hospital 9,822 (35.50) 217 (42.14) 18,480 (38.96) 391 (45.92) 
 
Children's unit in a general hospital 13,157 (47.55) 228 (44.27) 21,269 (44.84) 345 (40.51) 
Table 3.2 Hospital characteristics of SOT admissions and SOT admissions with CDI 
 
45 
 
CDI= clostridium difficile infection; SOT= solid organ transplant 
3.3.3 Objective 3 
Objective 3 was to describe CDI prevalence of admissions among pediatric SOT 
patients. The number of SOT admissions and the corresponding prevalence of CDI 
were categorized by types of organ transplant in Table 3.3. For weighted admissions, 
the largest proportion of SOT events was associated with kidney transplants (41.5%), 
and the second largest proportion was liver transplants (36.0%).  
Overall, the prevalence of CDI in weighted SOT admissions was 1.76%. 
Admissions with intestine transplant had the highest CDI prevalence (2.90%), 
followed by lung (2.54%) and liver (2.43%) transplant. Among all type of organ 
transplant, kidney transplant admissions had the lowest CDI prevalence (1.14%). 
 
 
Unweighted  Weighted 
Organ 
transplanted 
Number of 
admissions, n (%) 
CDI 
prevalence, % 
 Number of 
admissions, n (%) 
CDI 
prevalence, % 
Any organ 28185 (100.00) 1.83  48286 (100.00) 1.76 
Heart 4544 (16.12) 1.61  7868 (16.30) 1.57 
Liver 10103 (35.85) 2.56  17376 (35.99) 2.43 
Lung 1091 (3.87) 2.57  1927 (3.99) 2.54 
Kidney 11784 (41.81) 1.16  20035 (41.49) 1.14 
Pancreas 72 (0.26) 1.39  119 (0.25) 1.26 
Intestine 591 (2.10) 2.88  961 (1.99) 2.90 
 
 
  
Table 3.3 Number of SOT admissions and the corresponding prevalence of CDI 
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CDI= clostridium difficile infection; SOT= solid organ transplant; LOS= length of stay; SE= standard error 
3.3.4 Objective 4 
Objective 4 was to describe the outcomes regarding transplant failure or 
rejections, hospital mortality, colectomies, and hospital length of stay for admissions 
of pediatric SOT patients. Descriptive statistics for these outcome variables are shown 
in Table 3.4. 
 Hospitalizations for SOT patients with CDI had higher mortality and 
colectomy rates than SOT hospitalizations without CDI (1.63% vs. 1.14% for 
mortality; 4.86% vs. 2.52% for colectomy), while the rate of transplant 
failure/rejections was lower (34.17% vs. 27.71%). The hospital length of stay (LOS) 
for patients with both SOT and CDI was more than twice as long as the LOS with 
SOT only (median: 7 days vs. 3 days; mean (SE): 17 days (1.32) vs. 8 days (0.28)). 
 
 
 
 
 
 
 
  
  
Unweighted  Weighted 
Variable SOT only SOT+CDI  SOT only SOT+CDI 
Mortality, % 1.11 1.55  1.14 1.63 
Transplant failure or rejection, % 34.59 27.96  34.17 27.71 
Colectomy, % 2.58 4.85  2.52 4.86 
LOS, days 
  
 
  
 
Median 3 7  3 7
 
Mean (SE) 8 (0.28) 17 (1.33)  8 (0.28) 17 (1.32) 
Table 3.4 Outcomes of SOT admissions and SOT admissions with CDI 
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CDI= clostridium difficile infection; SOT= solid organ transplant; SE= standard error 
*rounded to the nearest dollar 
3.3.5 Objective 5 
Objective 5 was to estimate the hospital charges and hospital costs of pediatric 
SOT admissions. All charges and costs are reported in 2009 US dollars. Estimations 
of charges and corresponding costs for SOT admissions and SOT admissions with 
CDI are shown in Table 3.5. 
SOT admissions with CDI had higher median charges and median costs than 
SOT admissions without CDI (charges: $48,409 vs. $21,022; costs: $17,412 vs. 
$8,662). The mean charge per SOT admission was $67,629 (SE=$3,838) while the 
mean charge per SOT admission with CDI was $137,874 (SE=$12,338). The mean 
cost per SOT admission was $26,652 (SE=$1,510) while the mean cost per SOT 
admission with CDI was $49,471 (SE=$5,261). 
 
 
  
Unweighted Weighted 
Variable SOT only SOT+CDI SOT only SOT+CDI 
Charges, $ 
    
 
Median* 21,750 48,633 21,022 48,409
 
Mean* (SE) 68,716 (3,664) 138,208 (12,649) 67,629 (3,838) 137,874 (12,338) 
Costs, $ 
    
 
Median* 8,686 17,631 8,662 17,412
 
Mean* (SE) 26,559 (1,425) 49,919 (5,242) 26,652 (1,510) 49,471 (5,261) 
 
 
 
 
 
 
 
3.3.6 Objective 6 
Table 3.5 Charges and costs of SOT admissions and SOT admissions with CDI 
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Objective 6 was to determine if the presence of CDI was significantly associated 
with hospital mortality in pediatric SOT patients while controlling for other 
covariates. A logistic regression with hospital mortality as the dependent variable and 
presence of CDI as the independent variables was employed while controlling for the 
following covariates: age, gender, race, payer type, household income, UTI, 
pneumonia, CMV, PTLD, CCI, organ transplant type, hospital size, hospital 
geographic region, teaching status, and children’s general or specialty hospital. The 
category—pancreas—in variable of transplant type was excluded from the regression 
model because no event occurred under this category. Table 3.6 provides the odds 
ratios, standard errors, t values, and 95% confidence intervals for the independent 
variable and all covariates. 
The overall regression model was statistically significant (F=23.12, p<0.001). 
There was no significant difference in hospital mortality between patients with SOT 
admissions with CDI and patients with SOT admissions without CDI while 
controlling for other covariates (OR=1.41, 95% CI= [0.63, 3.13], p=0.40).  
 Regarding the covariates, admissions that were “self-pay” had more than 3 
times the likelihood of hospital mortality compared to admissions with “private 
insurance” as the primary payer (OR=3.27, 95% CI= [1.30, 8.24], p=0.01). 
Admissions with a co-morbidity of pneumonia had double the likelihood of hospital 
mortality than those without this diagnosis (OR=2.14, 95% CI= [1.52, 3.00], 
p<0.001). Pediatric SOT admissions with greater comorbid burdens (CCI=1 and 
CCI=2) had higher likelihoods of hospital mortality than pediatric SOT admissions 
with no comorbid burden (CCI=0) while controlling for other covariates (For CCI=1: 
OR=2.67, 95% CI= [1.98, 3.61], p<0.001; For CCI=2: OR=5.12, 95% CI= [3.34, 
7.86], p<0.001). Compared to admissions for kidney transplant patients, heart, liver, 
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lung, and intestine transplant admissions had higher rates of hospital mortality (Heart: 
OR=12.31, 95% CI= [5.78, 26.21], p<0.001; Liver: OR=6.33, 95% CI= [3.59, 11.16], 
p<0.001; Lung: OR=19.22, 95% CI= [9.35, 39.51], p<0.001; Intestine: OR=9.50, 95% 
CI= [3.81, 23.69], p<0.001;). Admission to a teaching hospital was also significantly 
associated with a higher mortality rate. Patients with SOT events in teaching hospitals 
were approximately 7 times more likely to die during hospitalization compared to 
patients in non-teaching hospitals while controlling for the other factors (OR=6.79, 
95% CI= [1.49, 30.90], p=0.01). 
 
H1: There is a significant difference in the likelihood of inpatient mortality between 
pediatric SOT patient with CDI and pediatric SOT patients without CDI while 
controlling for other covariates. [Rejected]      
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Variable 
Odds 
Ratio SE t 95% CI p-value 
Presence of CDI (ref=without CDI) 1.41 0.57 0.84 0.63 3.13 0.40 
Age (ref=1~4 Years old) 
      
 
5~9 Years old 0.63 0.14 -2.04 0.40 0.98 0.04* 
 
10~14 Years old 0.73 0.15 -1.55 0.50 1.08 0.12 
 
15~17 Years old 0.75 0.15 -1.41 0.50 1.12 0.16 
Gender (ref=male) 
      
 
Female  0.96 0.12 -0.34 0.75 1.23 0.74 
Race (ref=White) 
      
 
Black 1.41 0.34 1.40 0.87 2.28 0.16 
 
Hispanic 0.94 0.17 -0.32 0.66 1.35 0.75 
 
Other† 0.99 0.24 -0.04 0.61 1.60 0.97 
Payer (ref=Private insurance) 
      
 
Medicare 0.83 0.28 -0.55 0.42 1.63 0.58 
 
Medicaid 0.87 0.16 -0.72 0.61 1.26 0.48 
 
Self-pay 3.27 1.54 2.52 1.30 8.24 0.01* 
 
Other‡ 1.27 0.31 1.00 0.79 2.04 0.32 
Income quartiles for ZIP code  
(ref=0th~25th percentile) 
    
 
26th~50th percentile 1.09 0.14 0.69 0.85 1.41 0.49 
 
51th~75th percentile 0.82 0.18 -0.91 0.53 1.26 0.36 
 
76th~100th percentile 0.73 0.15 -1.48 0.49 1.11 0.14 
Comorbid condition  
(ref=without specific infection) 
     
 
UTI 1.17 0.82 0.23 0.30 4.62 0.82 
 
Pneumonia 2.14 0.37 4.40 1.52 3.00 <0.001* 
 
CMV 1.80 0.52 2.03 1.02 3.18 0.04* 
 
PTLD 0.45 0.20 -1.81 0.19 1.07 0.07 
Charlson Comorbidity Index (ref= CCI=0) 
      CCI=1 2.67 0.41 6.39 1.98 3.61 <0.001* 
 
CCI≥2  5.12 1.12 7.49 3.34 7.86 <0.001* 
Transplant organ (ref=kidney) 
      
 
Heart 12.31 4.74 6.52 5.78 26.21 <0.001* 
 
Liver 6.33 1.83 6.39 3.59 11.16 <0.001* 
 
Lung 19.22 7.05 8.06 9.35 39.51 <0.001* 
 
Intestine 9.50 4.42 4.84 3.81 23.69 <0.001* 
Hospital size (ref=small) 
      
 
Medium 1.38 0.42 1.07 0.76 2.51 0.28 
 
Large 1.46 0.57 0.97 0.68 3.13 0.33 
Hospital geographic region (ref=Northeast) 
     
 
Midwest 1.18 0.39 0.50 0.61 2.28 0.62 
 
South 0.95 0.22 -0.24 0.60 1.50 0.81 
 
West 1.15 0.24 0.65 0.76 1.72 0.51 
Teaching status (ref=non-teaching hospital) 
     
 
Teaching hospital 6.79 5.24 2.48 1.49 30.90 0.01* 
Table 3.6 Logistic regression analysis for hospital mortality of SOT admissions 
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CDI= clostridium difficile infection; SOT= solid organ transplant; UTI= Urinary tract infaction ; CMV= cytomegalovirus; PTLD= 
post-transplant lymphoproliferative disease; CCI= Charlson comorbidity index 
†includes Asian or Pacific Islander, Native American, and other 
‡includes charity funding, treatment as part of special research, medically indigent patient, or free care, worker's Compensation, 
Civilian Health and Medical Program of the Uniformed Services (CHAMPUS), Civilian Health and Medical Program of the 
Department of Veterans Affairs (CHAMPVA), Title V, and other government programs 
*significant at p<0.05 
 
Children's general or specialty hospital  
(ref=not identified as children's hospital) 
  
 
Children's general or specialty hospital 0.89 0.32 -0.34 0.44 1.79 0.74 
 
Children's unit in a general hospital 0.74 0.33 -0.68 0.31 1.78 0.50 
 
 
 
 
 
 
 
  
Table 3.6 Logistic regression analysis for hospital mortality of SOT admissions (cont’d) 
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3.3.7 Objective 7 
Objective 7 was to determine if the presence of CDI was significantly associated 
with transplant failure or rejection while controlling for other covariates. A logistic 
regression with having a transplant failure or rejection event as the dependent variable 
and presence of CDI as the independent variables was employed while controlling for 
the following covariates: age, gender, race, payer type, household income, UTI, 
pneumonia, CMV, PTLD, CCI, organ transplant type, hospital size, hospital 
geographic region, teaching status, and children’s general or specialty hospital. Table 
3.7 provides the odds ratios, standard errors, t values, and 95% confidence intervals 
for the independent variable and all covariates. 
The overall regression model was statistically significant (F=22.20, p<0.001). 
There was no significant difference in transplant failure or rejection event between 
pediatric SOT admissions with CDI and pediatric SOT admissions without CDI while 
controlling for other covariates (OR=0.82, 95% CI= [0.63, 1.07], p=0.15).  
 Regarding the covariates, age was significantly associated with transplant 
failure or rejection in SOT admissions. Patients in older age groups had a higher 
likelihood of having transplant failure or rejection during SOT admissions while 
controlling for other factors. Patients aged 5~9 years old, 10~14 years old, and 15~17 
years old were more likely to have transplant failure/rejection during SOT admissions 
compared to patients aged 1~4 years old (5~9 years old: OR=1.26, 95% CI= [1.10, 
1.43], p<0.001; 10~14 years old: OR=1.56, 95% CI= [1.40, 1.74], p<0.001; 15~17 
years old: OR=1.81, 95% CI= [1.58, 2.08], p<0.001). Compared to White SOT 
recipients, the odds of having transplant failure or rejection were 22% higher for 
Black SOT recipients while controlling for other factors (OR=1.22, 95% CI= [1.09, 
1.38], p<0.001). 
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Pediatric SOT admissions with Medicare as the expected primary payer were 
27% more likely to have transplant failure/rejection when compared to SOT 
admission with private insurance as the expected primary payer (OR=1.27, 95% CI= 
[1.12, 1.43], p<0.001). Pediatric SOT admissions with other primary payers (charity 
funding, treatment as part of special research, medically indigent patient, or free care, 
worker's Compensation, Civilian Health and Medical Program of the Uniformed 
Services (CHAMPUS), Civilian Health and Medical Program of the Department of 
Veterans Affairs (CHAMPVA), Title V, and other government programs) were 30% 
more likely to have transplant failure/rejection when compared to pediatric SOT 
admissions with private insurance as expected primary payer (OR=1.30, 95% CI= 
[1.06, 1.60], p=0.01). 
For comorbid conditions, pediatric SOT admissions with UTI were 64% more 
likely to have transplant failure/rejection compared to pediatric SOT admissions 
without UTI while controlling for other factors (OR=1.64, 95% CI= [1.27, 2.11], 
p<0.001). Pediatric SOT admissions with CMV were 3 times more likely to have 
transplant failure/rejection compared to pediatric SOT admissions without CMV 
while controlling for other factors (OR=3.18, 95% CI= [2.44, 4.15], p<0.001). 
However, the results indicated that pediatric SOT admissions with pneumonia was 
less likely to have transplant failure/rejection when other factors were held constant 
(Pneumonia: OR=0.59, 95% CI= [0.50, 0.70], p<0.001).  
Pediatric SOT admissions with greater comorbid burdens (CCI=1 and CCI=2) 
had higher likelihoods to have transplant failure/rejection than pediatric SOT 
admissions with no comorbid burden (CCI=0) while controlling for other covariates 
(For CCI=1: OR=1.21, 95% CI= [1.05, 1.39], p=0.01; For CCI=2: OR=1.39, 95% CI= 
[1.26, 1.53], p<0.001). 
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When holding other factors constant, lung transplant patients were about 3 times 
more likely to have a transplant failure/rejection compared to patients with kidney 
transplants (OR=3.05, 95% CI= [1.95, 4.78], p<0.001).  
Patients with SOT admissions to teaching hospitals were 49% more likely to 
have transplant failure/rejection compared to patients in non-teaching hospitals while 
controlling for the other factors (OR=1.55, 95% CI= [1.15, 2.09], p=0.01), and those 
with admissions to children’s general or specialty hospitals were 48% more likely to 
have a transplant failure or rejection compared to those not identified as children’s 
hospitals (OR=1.48, 95% CI= [1.07, 2.04], p=0.02); patients in a children’s unit in a 
general hospital were 2 times more likely to have a transplant failure/rejection 
compared to admissions to a hospital not identified as children’s hospitals (OR=1.96, 
95% CI= [1.52, 2.54], p<0.001). 
 
H2: There is a significant difference in the likelihood of having a transplant failure or 
rejection event during a hospitalization between pediatric SOT patients with CDI and 
pediatric SOT patients without CDI while controlling for other covariates. [Rejected]   
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Variable 
Odds 
Ratio SE t 95% CI p-value 
Presence of CDI (ref=without CDI) 0.82 0.11 -1.45 0.63 1.07 0.15 
Age (ref=1~4 Years old) 
      
 
5~9 Years old 1.26 0.08 3.46 1.10 1.43 <0.001* 
 
10~14 Years old 1.56 0.09 8.19 1.40 1.74 <0.001* 
 
15~17 Years old 1.81 0.13 8.46 1.58 2.08 <0.001* 
Gender (ref=male) 
      
 
Female  1.04 0.03 1.06 0.97 1.11 0.29 
Race (ref=White) 
      
 
Black 1.22 0.07 3.41 1.09 1.38 <0.001* 
 
Hispanic 0.93 0.06 -1.02 0.82 1.06 0.31 
 
Other† 0.94 0.08 -0.70 0.79 1.12 0.49 
Payer (ref=Private insurance) 
      
 
Medicare 1.27 0.08 3.80 1.12 1.43 <0.001* 
 
Medicaid 1.10 0.06 1.75 0.99 1.23 0.08 
 
Self-pay 1.30 0.38 0.89 0.73 2.29 0.37 
 
Other‡ 1.30 0.14 2.48 1.06 1.60 0.01* 
Income quartiles for ZIP code  
(ref=0th~25th percentile) 
    
 
26th~50th percentile 1.00 0.05 0.05 0.91 1.10 0.96 
 
51th~75th percentile 0.94 0.06 -0.97 0.83 1.06 0.33 
 
76th~100th percentile 0.90 0.07 -1.32 0.78 1.05 0.19 
Comorbid condition  
(ref=without specific infection) 
     
 
UTI 1.64 0.21 3.82 1.27 2.11 <0.001* 
 
Pneumonia 0.59 0.05 -6.00 0.50 0.70 <0.001* 
 
CMV 3.18 0.43 8.59 2.44 4.15 <0.001* 
 
PTLD 0.66 0.14 -1.91 0.43 1.01 0.06 
Charlson Comorbidity Index (ref= CCI=0) 
      CCI=1 1.21 0.09 2.58 1.05 1.39 0.01* 
 
CCI≥2  1.39 0.07 6.73 1.26 1.53 <0.001* 
Transplant organ (ref=kidney) 
      
 
Heart 0.94 0.08 -0.71 0.80 1.11 0.48 
 
Liver 0.91 0.06 -1.42 0.80 1.04 0.16 
 
Lung 3.05 0.70 4.87 1.95 4.78 <0.001* 
 
Pancreas 0.88 0.34 -0.33 0.41 1.88 0.74 
 
Intestine 1.04 0.15 0.25 0.78 1.37 0.80 
Hospital size (ref=small) 
      
 
Medium 1.20 0.13 1.65 0.97 1.50 0.10 
 
Large 1.18 0.21 0.97 0.84 1.67 0.33 
Hospital geographic region (ref=Northeast) 
     
 
Midwest 1.00 0.15 0.00 0.74 1.34 1.00 
 
South 1.03 0.12 0.23 0.81 1.30 0.82 
 
West 1.05 0.12 0.47 0.84 1.32 0.64 
Teaching status (ref=non-teaching hospital) 
     
Table 3.7 Logistic regression for the prevalence of transplant failure/rejection in SOT admissions 
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CDI= clostridium difficile infection; SOT= solid organ transplant; UTI= Urinary tract infaction ; CMV= cytomegalovirus; PTLD= 
post-transplant lymphoproliferative disease; CCI= Charlson comorbidity index 
†includes Asian or Pacific Islander, Native American, and other 
‡includes charity funding, treatment as part of special research, medically indigent patient, or free care, worker's Compensation, 
Civilian Health and Medical Program of the Uniformed Services (CHAMPUS), Civilian Health and Medical Program of the 
Department of Veterans Affairs (CHAMPVA), Title V, and other government programs 
*significant at p<0.05 
 
Table 3.7 Logistic regression for the prevalence of transplant failure/rejection in SOT admissions (cont’d) 
 
Teaching hospital 1.55 0.24 2.91 1.15 2.09 0.01* 
Children's general or specialty hospital  
(ref=not identified as children's hospital) 
  
 
Children's general or specialty hospital 1.48 0.24 2.38 1.07 2.04 0.02* 
 
Children's unit in a general hospital 1.96 0.26 5.12 1.52 2.54 <0.001* 
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3.3.8 Objective 8 
Objective 8 was to determine if the presence of CDI was significantly associated 
with a colectomy while controlling for other covariates. A logistic regression with 
having a colectomy event as the dependent variable and presence of CDI as the 
independent variable was employed while controlling for the following covariates: 
age, gender, race, payer type, household income, UTI, pneumonia, CMV, PTLD, CCI, 
organ transplant type, hospital size, hospital geographic region, teaching status, and 
children’s general or specialty hospital. The category—pancreas—in variable of 
transplant type was excluded from the regression model because no event occurred 
under this category. Table 3.8 provides the odds ratios, standard errors, t values, and 
95% confidence intervals for the independent variable and all covariates. 
The overall regression model was statistically significant (F=10.17, p<0.001). 
The results showed that pediatric SOT admissions with CDI diagnosis were 2.6 times 
more likely to include colectomy than admission for SOT without CDI while 
controlling for other covariates (OR=2.624 95% CI= [1.64, 4.24], p<0.001).  
 Regarding the covariates, patients aged 15~17 years old were 46% more likely 
to have a colectomy compared to patients aged 1~4 years old (OR=1.46, 95% CI= 
[1.06, 2.00], p=0.02).  
For comorbid conditions, pediatric SOT admissions with PTLD were 65% less 
likely to have colectomy compared to pediatric SOT admissions without PTLD while 
controlling for other factors (OR=0.35, 95% CI= [0.16, 0.81], p=0.01).  
Pediatric SOT admissions with greater comorbid burdens (CCI=1 and CCI=2) 
had higher likelihoods to have colectomy than pediatric SOT admissions with no 
comorbid burden (CCI=0) while controlling for other covariates (For CCI=1: 
OR=1.69, 95% CI= [1.24, 2.30], p<0.001; For CCI=2: OR=2.24, 95% CI= [1.74, 
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2.89], p<0.001).  
When holding other factors constant, patients with heart transplants were 89% 
more likely to have a colectomy compared to patients with kidney transplants 
(OR=1.89, 95% CI= [1.35, 2.64], p<0.001); patients with intestine transplants were 2 
times more likely to have a colectomy compared to patients with kidney transplants 
(OR=2.09, 95% CI= [1.28, 3.44], p<0.001).  
While holding other factors constant, admissions to children’s general or 
specialty hospitals were 2 times more likely to include a colectomy compared to those 
not identified as children’s hospitals (OR=1.97, 95% CI= [1.11, 3.50], p=0.02). 
 
H3: There is a significant difference in the likelihood of having a colectomy during a 
hospitalization between pediatric SOT patients with CDI and pediatric SOT patients 
without CDI while controlling for other covariates. [Not rejected]   
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Variable 
Odds 
Ratio SE t 95% CI p-value 
Presence of CDI (ref=without CDI) 2.64 0.64 4.01 1.64 4.24 <0.001* 
Age (ref=1~4 Years old) 
      
 
5~9 Years old 1.08 0.16 0.53 0.81 1.44 0.60 
 
10~14 Years old 1.20 0.17 1.30 0.91 1.59 0.19 
 
15~17 Years old 1.46 0.24 2.32 1.06 2.00 0.02* 
Gender (ref=male) 
      
 
Female  0.96 0.10 -0.40 0.79 1.17 0.69 
Race (ref=White) 
      
 
Black 1.17 0.17 1.07 0.88 1.56 0.28 
 
Hispanic 0.90 0.17 -0.56 0.62 1.30 0.58 
 
Other† 1.30 0.20 1.69 0.96 1.77 0.09 
Payer (ref=Private insurance) 
      
 
Medicare 0.99 0.18 -0.04 0.69 1.43 0.97 
 
Medicaid 0.80 0.09 -2.01 0.64 0.99 0.05 
 
Self-pay 0.74 0.43 -0.53 0.24 2.30 0.60 
 
Other‡ 1.07 0.19 0.37 0.75 1.53 0.72 
Income quartiles for ZIP code  
(ref=0th~25th percentile) 
    
 
26th~50th percentile 0.91 0.11 -0.76 0.72 1.16 0.45 
 
51th~75th percentile 0.96 0.12 -0.36 0.75 1.22 0.72 
 
76th~100th percentile 0.80 0.11 -1.55 0.61 1.06 0.12 
Comorbid condition  
(ref=without specific infection) 
     
 
UTI 1.25 0.37 0.76 0.70 2.23 0.45 
 
Pneumonia 0.82 0.12 -1.31 0.61 1.10 0.19 
 
CMV 1.43 0.36 1.40 0.87 2.35 0.16 
 
PTLD 0.35 0.15 -2.46 0.16 0.81 0.01* 
Charlson Comorbidity Index (ref= CCI=0) 
      CCI=1 1.69 0.27 3.34 1.24 2.30 <0.001* 
 
CCI≥2  2.24 0.29 6.28 1.74 2.89 <0.001* 
Transplant organ (ref=kidney) 
      
 
Heart 1.89 0.32 3.71 1.35 2.64 <0.001* 
 
Liver 0.86 0.12 -1.10 0.65 1.13 0.27 
 
Lung 1.05 0.41 0.13 0.49 2.25 0.90 
 
Intestine 2.09 0.53 2.93 1.28 3.44 <0.001* 
Hospital size (ref=small) 
      
 
Medium 1.39 0.29 1.56 0.92 2.09 0.12 
 
Large 1.32 0.32 1.16 0.82 2.12 0.25 
Hospital geographic region (ref=Northeast) 
     
 
Midwest 1.19 0.33 0.64 0.70 2.04 0.52 
 
South 1.14 0.23 0.66 0.77 1.70 0.51 
 
West 1.20 0.23 0.95 0.83 1.73 0.34 
Teaching status (ref=non-teaching hospital) 
     
 
Teaching hospital 0.93 0.34 -0.19 0.45 1.93 0.85 
Table 3.8 Logistic regression for the prevalence of colectomy in SOT admissions 
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CDI= clostridium difficile infection; SOT= solid organ transplant; UTI= Urinary tract infaction ; CMV= cytomegalovirus; PTLD= 
post-transplant lymphoproliferative disease; CCI= Charlson comorbidity index 
†includes Asian or Pacific Islander, Native American, and other 
‡includes charity funding, treatment as part of special research, medically indigent patient, or free care, worker's Compensation, 
Civilian Health and Medical Program of the Uniformed Services (CHAMPUS), Civilian Health and Medical Program of the 
Department of Veterans Affairs (CHAMPVA), Title V, and other government programs 
*significant at p<0.05 
 
Children's general or specialty hospital  
(ref=not identified as children's hospital) 
  
 
Children's general or specialty hospital 1.97 0.58 2.31 1.11 3.50 0.02* 
 
Children's unit in a general hospital 1.83 0.65 1.71 0.91 3.67 0.09 
 
  
Table 3.8 Logistic regression for the prevalence of colectomy in SOT admissions (cont’d) 
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3.3.9 Objective 9 
Objective 9 was to determine if the presence of CDI was significantly associated 
with hospital length of stay (LOS) for SOT admissions while controlling for other 
covariates. A gamma regression with log link with LOS as the dependent variable and 
the presence of CDI as the independent variables was used while controlling for the 
following covariates: age, gender, race, payer type, household income, UTI, 
pneumonia, CMV, PTLD, CCI, organ transplant type, hospital size, hospital 
geographic region, teaching status, and children’s general or specialty hospital. Table 
3.9 provides the coefficients, standard errors, t values, and 95% confidence intervals 
for the independent variable and all covariates.  
All coefficients in Table 3.9 are arithmetic mean ratios of hospital LOS (in 
number of days) for SOT admissions under that specific category versus hospital LOS 
(in number of days) for SOT admissions under the reference category. Therefore, the 
mean hospital LOS for a SOT admission with CDI was almost twice as long as the 
mean hospital LOS for a SOT admission without CDI (coefficient=1.92, 95% CI= 
[1.67, 2.20], p<0.001). 
The following covariates were significantly associated with a longer length of 
stay (LOS) in the hospital among SOT admissions: expected primary payer 
category—Medicare and Medicaid versus private insurance; presence of pneumonia 
and CMV; CCI=1 and CCI≥2 versus CCI=0; organ transplant type categories—heart, 
liver, lung, pancreas, and intestine versus kidney; teaching hospital; hospital was 
identified as a children’s general or specialty hospital versus hospital was not 
identified as a children’s hospital; and hospital was identified as a children’s unit in a 
general hospital versus hospital was not identified as a children’s hospitals. 
The covariates that were significantly associated with a shorter length of stay in 
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hospitals include: age groups—5~9 years old, 10~14 years old, 15~17 years old 
versus 1~4 years old, income quartiles categories—51th~75th percentile and 
76th~100th percentile versus 0th~25th percentile, and the presence of PTLD. 
 
H4: There is a significant difference in hospital length of stay (LOS) between 
pediatric SOT admissions with CDI and pediatric SOT admissions without CDI while 
controlling for other covariates. [Not rejected]   
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Variable Coefficient§ SE t 95% CI p-value 
Presence of CDI (ref=without CDI) 1.92 0.13 9.29 1.67 2.20 <0.001* 
Age (ref=1~4 Years old) 
      
 
5~9 Years old 0.87 0.03 -3.83 0.81 0.93 <0.001* 
 
10~14 Years old 0.80 0.03 -6.03 0.75 0.86 <0.001* 
 
15~17 Years old 0.84 0.03 -4.61 0.78 0.91 <0.001* 
Gender (ref=male) 
      
 
Female  1.04 0.03 1.47 0.99 1.09 0.14 
Race (ref=White) 
      
 
Black 1.05 0.04 1.09 0.97 1.13 0.28 
 
Hispanic 1.02 0.04 0.52 0.95 1.10 0.60 
 
Other† 1.05 0.04 1.22 0.97 1.14 0.22 
Payer (ref=Private insurance) 
      
 
Medicare 1.13 0.04 3.71 1.06 1.20 <0.001* 
 
Medicaid 1.09 0.04 2.57 1.02 1.16 0.01* 
 
Self-pay 1.04 0.12 0.35 0.83 1.30 0.72 
 
Other‡ 1.05 0.07 0.83 0.93 1.19 0.41 
Income quartiles for ZIP code  
(ref=0th~25th percentile) 
    
 
26th~50th percentile 0.97 0.03 -1.11 0.91 1.03 0.27 
 
51th~75th percentile 0.92 0.03 -2.47 0.86 0.98 0.01* 
 
76th~100th percentile 0.90 0.03 -2.80 0.84 0.97 0.01* 
Comorbid condition  
(ref=without specific infection) 
     
 
UTI 1.05 0.05 0.99 0.96 1.14 0.32 
 
Pneumonia 1.38 0.08 5.32 1.22 1.55 <0.001* 
 
CMV 1.48 0.10 5.55 1.29 1.70 <0.001* 
 
PTLD 0.73 0.07 -3.33 0.61 0.88 <0.001* 
Charlson Comorbidity Index (ref= CCI=0) 
      CCI=1 1.83 0.09 12.67 1.67 2.01 <0.001* 
 
CCI≥2  2.01 0.07 19.06 1.87 2.16 <0.001* 
Transplant organ (ref=kidney) 
      
 
Heart 1.71 0.11 8.65 1.51 1.93 <0.001* 
 
Liver 1.44 0.07 7.86 1.31 1.58 <0.001* 
 
Lung 1.98 0.19 7.04 1.64 2.40 <0.001* 
 
Pancreas 3.04 0.76 4.47 1.87 4.95 <0.001* 
 
Intestine 2.47 0.25 8.79 2.02 3.02 <0.001* 
Hospital size (ref=small) 
      
 
Medium 1.02 0.08 0.19 0.87 1.19 0.85 
 
Large 1.09 0.09 1.08 0.93 1.28 0.28 
Hospital geographic region (ref=Northeast) 
     
 
Midwest 0.92 0.07 -1.15 0.80 1.06 0.25 
 
South 0.98 0.05 -0.33 0.88 1.09 0.74 
 
West 0.93 0.06 -1.03 0.82 1.06 0.30 
Teaching status (ref=non-teaching hospital) 
     
 
Teaching hospital 1.27 0.13 2.41 1.05 1.54 0.02* 
Table 3.9 Log-linked gamma regression to assess hospital LOS for SOT admissions 
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CDI= clostridium difficile infection; SOT= solid organ transplant; UTI= Urinary tract infaction ; CMV= cytomegalovirus; PTLD= 
post-transplant lymphoproliferative disease; CCI= Charlson comorbidity index 
†includes Asian or Pacific Islander, Native American, and other 
‡includes charity funding, treatment as part of special research, medically indigent patient, or free care, worker's Compensation, 
Civilian Health and Medical Program of the Uniformed Services (CHAMPUS), Civilian Health and Medical Program of the 
Department of Veterans Affairs (CHAMPVA), Title V, and other government programs 
*significant at p<0.05 
 
Children's general or specialty hospital  
(ref=not identified as children's hospital) 
  
 
Children's general or specialty hospital 1.56 0.11 6.52 1.36 1.78 <0.001* 
 
Children's unit in a general hospital 1.40 0.09 5.33 1.23 1.58 <0.001* 
 
Table 3.9 Log-linked gamma regression to assess hospital LOS for SOT admissions (cont’d) 
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3.3.10 Objective 10 
Objective 10 was to determine if the presence of CDI was significantly 
associated with hospital charges for SOT admissions while controlling for other 
covariates. A gamma regression with log link was used, with hospital charges as the 
dependent variable and the presence of CDI as the independent variables, while 
controlling for following covariates: age, gender, race, payer type, household income, 
UTI, pneumonia, CMV, PTLD, CCI, organ transplant type, hospital size, hospital 
geographic region, teaching status, and children’s general or specialty hospital. Table 
3.10 provides the coefficients, standard errors, t values, and 95% confidence intervals 
for the independent variable and all covariates.  
All coefficients in Table 3.10 are arithmetic mean ratios of charges (in 2009 US 
dollars) for SOT admissions under that specific category versus charges (in 2009 US 
dollars) for SOT admissions under the reference category. Therefore, the mean 
hospital charges for a SOT admission with CDI was about 2 times the mean hospital 
charges for a SOT admission without CDI (coefficient=1.99, 95% CI= [1.62, 2.44], 
p<0.001). 
The following covariates were significantly associated with higher charges 
among SOT admissions: presence of pneumonia and CMV; CCI=1 and CCI≥2 versus 
CCI=0; organ transplant type categories—heart, liver, lung, pancreas, and intestine 
versus kidney; teaching hospital; teaching hospital; hospital was identified as a 
children’s general or specialty hospital versus hospital was not identified as a 
children’s hospital; and hospital was identified as a children’s unit in a general 
hospital versus hospital was not identified as a children’s hospitals. 
The covariates that were significantly associated with lower charges include: age 
group—5~9 years old and 10~14 years old versus 1~4 years old; and the presence of 
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UTI and PTLD; and hospital geographic region category—Midwest versus Northeast. 
 
H5: There is a significant difference in hospital charges between pediatric SOT 
admissions with CDI and pediatric SOT admissions without CDI while controlling for 
other covariates. [Not rejected]   
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Variable Coefficient§ SE t 95% CI p-value 
Presence of CDI (ref=without CDI) 1.99 0.21 6.66 1.62 2.44 <0.001* 
Age (ref=1~4 Years old) 
      
 
5~9 Years old 0.88 0.04 -2.55 0.80 0.97 0.01* 
 
10~14 Years old 0.85 0.04 -3.63 0.78 0.93 <0.001* 
 
15~17 Years old 0.97 0.04 -0.71 0.89 1.06 0.48 
Gender (ref=male) 
      
 
Female  0.98 0.03 -0.47 0.92 1.05 0.64 
Race (ref=White) 
      
 
Black 1.03 0.06 0.48 0.92 1.15 0.63 
 
Hispanic 1.01 0.05 0.31 0.92 1.11 0.76 
 
Other† 1.10 0.06 1.69 0.98 1.22 0.09 
Payer (ref=Private insurance) 
      
 
Medicare 1.02 0.04 0.39 0.94 1.09 0.69 
 
Medicaid 1.00 0.03 -0.15 0.94 1.05 0.88 
 
Self-pay 1.12 0.16 0.80 0.85 1.49 0.42 
 
Other‡ 1.11 0.08 1.38 0.96 1.29 0.17 
Income quartiles for ZIP code  
(ref=0th~25th percentile) 
    
 
26th~50th percentile 0.94 0.03 -1.73 0.88 1.01 0.08 
 
51th~75th percentile 0.95 0.04 -1.34 0.88 1.02 0.18 
 
76th~100th percentile 0.91 0.04 -1.96 0.83 1.00 0.05 
Comorbid condition  
(ref=without specific infection) 
     
 
UTI 0.74 0.05 -4.23 0.65 0.85 <0.001* 
 
Pneumonia 1.20 0.08 2.63 1.05 1.38 0.01* 
 
CMV 1.37 0.10 4.18 1.18 1.59 <0.001* 
 
PTLD 0.52 0.06 -5.61 0.41 0.65 <0.001* 
Charlson Comorbidity Index (ref= CCI=0) 
      CCI=1 2.09 0.14 11.34 1.84 2.38 <0.001* 
 
CCI≥2 2.99 0.11 29.97 2.79 3.22 <0.001* 
Transplant organ (ref=kidney) 
      
 
Heart 1.94 0.16 8.14 1.65 2.27 <0.001* 
 
Liver 1.41 0.07 6.83 1.28 1.56 <0.001* 
 
Lung 2.37 0.27 7.46 1.89 2.97 <0.001* 
 
Pancreas 2.76 0.62 4.50 1.77 4.29 <0.001* 
 
Intestine 2.52 0.26 8.94 2.05 3.08 <0.001* 
Hospital size (ref=small) 
      
 
Medium 0.97 0.13 -0.24 0.74 1.26 0.81 
 
Large 1.14 0.15 0.98 0.88 1.47 0.33 
Hospital geographic region (ref=Northeast) 
     
 
Midwest 0.79 0.09 -2.21 0.64 0.97 0.03* 
 
South 0.90 0.10 -0.98 0.73 1.11 0.33 
 
West 1.18 0.13 1.51 0.95 1.48 0.13 
Teaching status (ref=non-teaching hospital) 
     
 
Teaching hospital 1.73 0.22 4.40 1.35 2.21 <0.001* 
Table 3.10 Log-linked gamma regression to assess hospital charges for SOT admissions 
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CDI= clostridium difficile infection; SOT= solid organ transplant; UTI= Urinary tract infaction ; CMV= cytomegalovirus; PTLD= 
post-transplant lymphoproliferative disease; CCI= Charlson comorbidity index 
†includes Asian or Pacific Islander, Native American, and other 
‡includes charity funding, treatment as part of special research, medically indigent patient, or free care, worker's Compensation, 
Civilian Health and Medical Program of the Uniformed Services (CHAMPUS), Civilian Health and Medical Program of the 
Department of Veterans Affairs (CHAMPVA), Title V, and other government programs 
*significant at p<0.05 
 
Children's general or specialty hospital  
(ref=not identified as children's hospital) 
  
 
Children's general or specialty hospital 1.98 0.24 5.60 1.56 2.51 <0.001* 
 
Children's unit in a general hospital 1.44 0.14 3.70 1.19 1.74 <0.001* 
 
  
Table 3.10 Log-linked gamma regression to assess hospital charges for SOT admissions (cont’d) 
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3.3.11 Objective 11 
Objective 11 was to determine if the presence of CDI was significantly 
associated with hospital costs for SOT admissions while controlling for other 
covariates. A gamma regression with log link was used, with hospital costs as the 
dependent variable and the presence of CDI as the independent variables, while 
controlling for the following covariates: age, gender, race, payer type, household 
income, UTI, pneumonia, CMV, PTLD, CCI, organ transplant type, hospital size, 
hospital geographic region, teaching status, and children’s general or specialty 
hospital. Table 3.11 provides the coefficients, standard errors, t values, and 95% 
confidence intervals for the independent variable and all covariates.  
All coefficients in Table 3.11 are arithmetic mean ratios of costs (in 2009 US 
dollars) for SOT admissions under that specific category versus costs (in 2009 US 
dollars) for SOT admissions under the reference category. Therefore, the mean 
hospital costs for a SOT admission with CDI was about 2 times the mean hospital 
costs for a SOT admission without CDI (coefficient=1.96, 95% CI= [1.49, 2.57], 
p<0.001). 
The following covariates were significantly associated with higher costs among 
SOT admissions: presence of pneumonia and CMV; CCI=1 and CCI≥2 versus CCI=0; 
organ transplant type categories—heart, liver, lung, pancreas, and intestine versus 
kidney; teaching hospital; hospital was identified as a children’s general or specialty 
hospital versus hospital was not identified as a children’s hospital; and hospital was 
identified as a children’s unit in a general hospital versus hospital was not identified 
as a children’s hospitals. 
The covariates that were significantly associated with lower charges include:  
age group—5~9 years old and 10~14 years old versus 1~4 years old; income quartiles 
70 
 
categories—26th~50th percentile versus 0th~25th percentile; the presence of UTI and 
PTLD. 
. 
H6: There is a significant difference in hospital costs between pediatric SOT 
admissions with CDI and pediatric SOT admissions without CDI while controlling for 
other covariates. [Not rejected] 
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Variable Coefficient§ SE t 95% CI p-value 
Presence of CDI (ref=without CDI) 1.96 0.27 4.88 1.49 2.57 <0.001* 
Age (ref=1~4 Years old) 
      
 
5~9 Years old 0.89 0.05 -2.21 0.80 0.99 0.03* 
 
10~14 Years old 0.91 0.04 -2.31 0.84 0.99 0.02* 
 
15~17 Years old 0.97 0.04 -0.87 0.90 1.04 0.39 
Gender (ref=male) 
      
 
Female  0.98 0.04 -0.40 0.91 1.07 0.69 
Race (ref=White) 
      
 
Black 0.98 0.05 -0.44 0.87 1.09 0.66 
 
Hispanic 0.95 0.05 -0.86 0.86 1.06 0.39 
 
Other† 1.09 0.06 1.58 0.98 1.22 0.12 
Payer (ref=Private insurance) 
      
 
Medicare 1.02 0.05 0.47 0.93 1.12 0.64 
 
Medicaid 0.96 0.03 -1.12 0.89 1.03 0.26 
 
Self-pay 0.92 0.23 -0.32 0.56 1.52 0.75 
 
Other‡ 1.16 0.09 1.84 0.99 1.36 0.07 
Income quartiles for ZIP code  
(ref=0th~25th percentile) 
    
 
26th~50th percentile 0.92 0.03 -2.22 0.85 0.99 0.03* 
 
51th~75th percentile 0.98 0.04 -0.55 0.90 1.06 0.58 
 
76th~100th percentile 0.94 0.05 -1.12 0.86 1.04 0.26 
Comorbid condition  
(ref=without specific infection) 
     
 
UTI 0.74 0.06 -4.02 0.64 0.86 <0.001* 
 
Pneumonia 1.16 0.08 2.07 1.01 1.34 0.04* 
 
CMV 1.62 0.16 5.00 1.34 1.95 <0.001* 
 
PTLD 0.55 0.07 -4.44 0.42 0.72 <0.001* 
Charlson Comorbidity Index (ref= CCI=0) 
      CCI=1 2.12 0.14 11.65 1.87 2.41 <0.001* 
 
CCI≥2  2.96 0.12 26.61 2.73 3.20 <0.001* 
Transplant organ (ref=kidney) 
      
 
Heart 1.98 0.13 10.52 1.74 2.25 <0.001* 
 
Liver 1.37 0.06 6.87 1.25 1.50 <0.001* 
 
Lung 2.07 0.17 8.62 1.75 2.44 <0.001* 
 
Pancreas 2.11 0.28 5.64 1.63 2.74 <0.001* 
 
Intestine 2.50 0.34 6.75 1.91 3.26 <0.001* 
Hospital size (ref=small) 
      
 
Medium 1.02 0.12 0.14 0.80 1.29 0.89 
 
Large 1.16 0.15 1.14 0.90 1.49 0.25 
Hospital geographic region (ref=Northeast) 
     
 
Midwest 1.01 0.09 0.06 0.84 1.21 0.96 
 
South 0.83 0.08 -2.01 0.69 1.00 0.05 
 
West 1.14 0.13 1.18 0.92 1.42 0.24 
Teaching status (ref=non-teaching hospital) 
     
 
Teaching hospital 1.98 0.23 5.92 1.58 2.49 <0.001* 
Table 3.11 Log-linked gamma regression to assess hospital costs for SOT admissions 
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CDI= clostridium difficile infection; SOT= solid organ transplant; UTI= Urinary tract infaction ; CMV= cytomegalovirus; PTLD= 
post-transplant lymphoproliferative disease; CCI= Charlson comorbidity index 
†includes Asian or Pacific Islander, Native American, and other 
‡includes charity funding, treatment as part of special research, medically indigent patient, or free care, worker's Compensation, 
Civilian Health and Medical Program of the Uniformed Services (CHAMPUS), Civilian Health and Medical Program of the 
Department of Veterans Affairs (CHAMPVA), Title V, and other government programs 
*significant at p<0.05 
 
Children's general or specialty hospital  
(ref=not identified as children's hospital) 
  
 
Children's general or specialty hospital 1.82 0.26 4.23 1.38 2.41 <0.001* 
 
Children's unit in a general hospital 1.47 0.16 3.48 1.18 1.82 <0.001* 
 
 
 
  
Table 3.11 Log-linked gamma regression to assess hospital costs for SOT admissions (cont’d) 
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A summary of all hypotheses tests results is presented in Table 3.12. 
 
 
Objectives Hypothesis Statistical test Result 
1. To describe the demographic 
characteristics based on hospital 
admissions of the pediatric SOT 
recipients with respect to age, 
gender, race, median household 
income for patient’s ZIP code, payer 
type, and comorbid condition. 
N/A Descriptive 
statistics  
N/A 
2. To describe the hospital-related 
characteristics of pediatric SOT 
admissions with respect to hospital 
size, location in rural or urban area, 
geographic regions, teaching status, 
and whether it is a children’s general 
hospital, children’s specialty 
hospital or children’s unit in a 
general hospital based on the 
National Association of Children’s 
Hospital and Related Institutions 
(NACHRI). 
N/A Descriptive 
statistics 
N/A 
3. To describe CDI prevalence based 
on hospital admissions among 
pediatric patient with SOT. 
N/A Descriptive 
statistics 
N/A 
4. To describe the outcomes 
regarding transplant failure or 
rejection events, hospital mortality, 
colectomies, and hospital length of 
stay among pediatric SOT patients. 
N/A Descriptive 
statistics 
N/A 
5. To estimate the charges (the 
amount that hospitals billed for 
services) and costs (charges multiply 
cost-to-charge ratios) of 
hospitalizations for pediatric 
N/A Descriptive 
statistics 
N/A 
Table 3.12 Results of hypotheses testing 
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patients with SOT. 
6. To determine if the presence of 
CDI is significantly associated with 
hospital mortality while controlling 
for other covariates (i.e., 
demographic characteristics, 
comorbid conditions, type of organ 
transplant, and hospital-related 
characteristics). 
H1: There is a significant 
difference in the likelihood 
of inpatient mortality 
between pediatric SOT 
patient with CDI and 
pediatric SOT patients 
without CDI while 
controlling for other 
covariates. 
Logistic 
regression 
Rejected 
7. To determine if the presence of 
CDI is significantly associated with 
transplant failures or rejections 
while controlling for other 
covariates (i.e., demographic 
characteristics, comorbid 
conditions, type of organ transplant, 
and hospital-related characteristics). 
H2: There is a significant 
difference in the likelihood 
of having a transplant 
failure or rejection event 
during a hospitalization 
between pediatric SOT 
patients with CDI and 
pediatric SOT patients 
without CDI while 
controlling for other 
covariates.  
Logistic 
regression 
Rejected 
8. To determine if the presence of 
CDI is significantly associated with 
having a colectomy while 
controlling for other covariates (i.e., 
demographic characteristics, 
comorbid conditions, type of organ 
transplant, and hospital-related 
characteristics). 
H3: There is a significant 
difference in the likelihood 
of having a colectomy 
during a hospitalization 
between pediatric SOT 
patients with CDI and 
pediatric SOT patients 
without CDI while 
controlling for other 
covariates. 
 
Logistic 
regression 
Not 
rejected 
9. To determine if the presence of 
CDI is significantly associated with 
hospital length of stay (LOS) for 
pediatric SOT patients while 
controlling for other covariates (i.e., 
demographic characteristics, 
comorbid conditions, type of organ 
transplant, and hospital-related 
characteristics). 
H4: There is a significant 
difference in hospital length 
of stay (LOS) between 
pediatric SOT admissions 
with CDI and pediatric 
SOT admissions without 
CDI while controlling for 
other covariates. 
Gamma 
regression 
with log link 
Not 
rejected 
10. To determine if the presence of 
CDI is significantly associated with 
charges (the amount that hospitals 
H5: There is a significant 
difference in hospital 
charges between pediatric 
Gamma 
regression 
Not 
rejected 
Table 3.12 Results of hypotheses testing (cont’d) 
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billed for services) for SOT 
hospitalizations while controlling 
for other covariates (i.e., 
demographic characteristics, 
comorbid conditions, type of organ 
transplant, and hospital-related 
characteristics). 
SOT admissions with CDI 
and pediatric SOT 
admissions without CDI 
while controlling for other 
covariates.  
 
with log link 
11. To determine if the presence of 
CDI is significantly associated with 
costs (charges multiply cost-to-
charge ratios) for SOT 
hospitalizations while controlling 
for other covariates (i.e., 
demographic characteristics, 
comorbid conditions, type of organ 
transplant, and hospital-related 
characteristics). 
H6: There is a significant 
difference in hospital costs 
between pediatric SOT 
admissions with CDI and 
pediatric SOT admissions 
without CDI while 
controlling for other 
covariates. 
 
Gamma 
regression 
with log link 
Not 
rejected 
 
 
 
 
 
  
CDI= clostridium difficile infection; SOT= solid organ transplant; LOS= length of stay 
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3.4 Post-hoc power analyses 
This study employed logistic regression and gamma log link regression analyses. 
Post-hoc power analyses were conducted in order to determine whether adequate 
statistical power based on actual sample sizes, odds ratios, and standard deviations 
from our observational data. The results of the post-hoc power analyses for each 
statistical procedure and its hypothesis testing are presented in Table 3.13. The results 
showed a wide range in power—from 0.09 to 0.99. Powers for H1, H2, H3, and H6 
were below the targeted power of 0.8. 
 
Hypothesis Dependent variable Statistical analysis Estimated 
power 
H1 Hospital mortality Logistic regression 0.09 
H2 Transplant rejection/failure Logistic regression 0.42 
H3 Colectomy Logistic regression 0.33 
H4 Length of stay Gamma regression with log link 0.99 
H5 Charges Gamma regression with log link 0.92 
H6 Costs Gamma regression with log link 0.70 
 
 
 
 
Table 3.13 Post-hoc power analyses 
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Chapter 4: Discussion 
4.1 Review of study purpose and results 
The aim of the present study was to evaluate the outcomes and expenditures of 
clostridium difficile infection (CDI) in pediatric solid organ transplant (SOT) 
recipients. We used the KID database from HCUP to generate national-level 
estimation. The overall prevalence of CDI for pediatric SOT events was 1.76%. For 
SOT admissions with CDI, hospital mortality was 1.63%; the prevalence of transplant 
failure or rejection event was 27.71%; the prevalence of a colectomy was 4.86%; the 
median length of stay in the hospital was seven days; the median hospital charge was 
$48,409; and the median hospital cost was $17,412. We found CDI was not 
significantly associated with higher mortality and transplant failure or rejection for 
pediatric SOT admissions. But CDI was significantly associated with a higher 
prevalence of a colectomy, a longer length of stay (LOS), higher hospital charges, and 
higher hospital costs. 
 
4.2 Demographic characteristics 
In this study, almost half the SOT admissions with CDI were for patients in the 
age category—1~4 years old (46.24%), followed by 5~9 years old (21.48%), 10~14 
years old (18.54%), and 15~17 years old (13.73%). This age distribution is consistent 
with the results of CDI among hospitalized children in a previous study.29 For the 
comorbid conditions, the prevalence of UTI in pediatric SOT events was less than the 
prevalence of UTI in adult SOT events (1.88% vs. 26.80%). This result may reflect 
the difference in the prevalence of UTI between children and adults—the prevalence 
of children with at least one UTI event before 10 years old was around 2.00%122,123; 
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while the prevalence of adults with UTI ranged from 2~50% depending on gender and 
the type of UTI.124,125 The majority pediatric SOT admissions were for patients with a 
score of zero on the CCI (SOT only: 62.29%; SOT+CDI: 67.37%) while most of the 
adult SOT admissions in the Pant et al. study were for patients with a CCI≥3 (SOT 
only: 58.4%; SOT+CDI: 66.6%).72 This may be due to the fact that the CCI was 
developed for adult patients, not for pediatric populations.107,108 
 
4.3 CDI prevalence 
Overall, the prevalence of CDI in weighted SOT admissions was 1.76%. 
Admissions for intestine transplants had the highest CDI prevalence (2.90%), 
followed by lung (2.54%) and liver (2.43%) transplants. Among all type of organ 
transplant admissions, kidney transplant events had the lowest CDI prevalence 
(1.14%). In the adult population, Riddle and Dubberke had proposed that the 
difference in prevalence among different types of organ transplant may partially 
because of hypogammaglobuilinemia (low levels of serum immunoglobulin) 
commonly associated with lung, liver, and heart transplants and this may increase the 
risk of infection after organ transplantation.62 In the pediatric population, several 
studies have also reported that hypogammaglobulinemia was observed after intestine, 
lung, and liver transplantation.126-128 The decrease of immunoglobulin level may make 
these children more susceptible to CDI. 
 
4.4 Post-hoc power analysis and sample size 
Logistic regression analyses showed that the presence of CDI was not 
significantly associated with hospital mortality and transplant failure or rejection. 
However, the powers regarding their corresponding hypothesis testing (H1 and H2) 
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were below our targeted power value—0.8 (Hospital mortality: power=0.09; 
transplant failure/rejection: power=0.42). The low powers could be due to a small 
difference between group means, large variability within study group, or inadequate 
sample sizes.129 The results indicated that the estimated sample sizes generated from 
adult populations were inadequate because of the different odds ratios for the presence 
of CDI between children and adults (OR for hospital mortality—adults: 2.48, 
children: 1.41; OR for transplant failure/rejection—adults: 1.36, children: 0.82).72 
Since a null hypothesis fails to be rejected if 1) no difference exist between group 
means; or 2) the power to adequately detect the test hypothesis is insufficient,129 the 
non-significance of the association between “CDI and hospital mortality (H1)” and the 
association between “CDI and transplant failure/rejection (H2)” may be because the 
power to detect a difference was low. 
Logistic regression showed that the presence of CDI was significantly associated 
with having a colectomy. However, the power for the corresponding hypothesis 
testing (H3: power=0.33) was relatively lower than our targeted power value—0.8. 
This indicated there was a great difference in having a colectomy between pediatric 
SOT admissions with CDI and pediatric SOT admissions without CDI. Therefore, 
although we had a small sample size, the difference between groups was still detected.  
Gamma regression with log link showed that the presence of CDI was 
significantly associated with hospital LOS. The power for the corresponding 
hypothesis testing (H4: power=0.99) was higher than our targeted power value—0.8. 
This indicated that we had adequate power to detect the difference between groups. 
The gamma regression with log link showed that the presence of CDI was 
significantly associated with hospital charges. The power for the corresponding 
hypothesis testing (H5: power=0.92) was higher than our targeted power value—0.8. 
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This indicated that we had adequate power to detect the difference between groups. 
Gamma regression with log link showed that the presence of CDI was 
significantly associated with hospital costs. The power for the corresponding 
hypothesis testing (H6: power=0.70) was relatively lower than our targeted power 
value—0.8. This indicated that the difference in hospital costs between pediatric SOT 
admissions with CDI and pediatric SOT admissions without CDI was relatively large. 
Therefore, although the power was slightly lower than our targeted value due to the 
sample size, the difference between groups was still detected. 
 
4.5 Mortality 
The mortality rate for pediatric SOT events with CDI was 1.63%. This is less 
than the mortality rate for adult SOT events with CDI—7.4% reported by Pant et al. 
in 2012.72 Previous studies have reported that a greater comorbid burden was 
significantly associated with an increased risk of patient death in adult solid organ 
transplants.72,130,131 Therefore, it is likely that this difference is due to the difference in 
comorbid conditions between pediatric and adult populations.  
In this study, the logistic regression procedure indicated that the presence of CDI 
was not significantly associated with hospital mortality after controlling for other 
covariates. One possible explanation is that pediatric transplant recipients stay in the 
intensive care unit and receive more medical surveillance than non-SOT patients. A 
previous study of adult SOT patients highlighted that close follow-up after 
transplantation might contribute to better outcomes for SOT patients with CDI.6  
 
4.6 Transplant failure or rejection 
The prevalence of a transplant failure or rejection for pediatric SOT events with 
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CDI was 27.71%. This is less than the prevalence for their adult counterpart—
38.1%.72 We found that there was no significant association between the prevalence of 
transplant failure or rejection and CDI using logistic regression analysis. Pant et al. 
had reported that CDI was significantly related to a higher risk of transplant failure or 
rejection in the adult population.72 The difference in transplant failure or rejection 
prevalence and its association with CDI may explained by the difference in age-
related immune functions between children and adults. For example, levels of 
adhesion receptor expression are age-dependent for different T cell subpopulations;87 
natural killer cell activity, proliferative response of T cells, cytotoxic response, and 
cytokine production are different in pediatric and adult populations.132 Therefore, 
children with less mature immune function may be more likely to get infection but 
they may be less likely to have strong adaptive immune responses to alloantigens on 
the graft and thus reduce the chance of having transplant failure or rejection.133 
Further investigation may be needed to elucidate the factors explaining the difference 
among the association of transplant failure or rejection and CDI for pediatric and 
adult populations. 
 
4.7 Colectomy 
The prevalence of a colectomy for pediatric SOT admission with CDI was 
4.86%, which is 2.6 times higher than SOT admissions without CDI. The result is 
higher than the colectomy prevalence in general CDI patients—1.25%—reported in 
the Kim et al. study.30 Keven et al. has proposed that the severity of CDI depends on 
the antibody-mediated response to clostridial toxins.67 Since SOT recipients use 
immunosuppression or monoclonal antibodies to prevent rejection, these factors may 
cause them to be more vulnerable to CDI and develop severe CDI, which often leads 
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to surgery to remove the diseased portion of the colon. The prevalence of colectomies 
in adult SOT events with CDI reported by Pant et al. was 1.1%, which is lower than 
the result from our pediatric population. A possible explanation is the difference in 
immune functions between children and adults. Another possible factor to consider is 
that the response to immunosuppression and the metabolism of immunosuppressant 
medications vary with age (e.g., T cells in infants are more sensitive than adult T cells 
to dexamethasone; pharmacokinetics of cyclosporine is different in children and 
adults).134,135 Further analysis may be required to explore the reason for the different 
prevalence of colectomies for SOT events with CDI in pediatric and adult 
populations. 
As we expected, because of the nature of CDI, the presence of a colectomy was 
significantly associated with CDI for SOT events while controlling other covariates in 
our logistic regression analysis. This is consistent with the results from an adult 
population in the Pant et al. study.72 A possible explanation for this association is 
that—hypogammaglobulinemia is common after pediatric organ transplantation.126-128 
The decrease in levels of immunoglobulin may weaken the immune system and lead 
to worse outcomes when the patient gets CDI. Another possible may be the 
emergence of the more-virulent clostridium difficile strain—BI/NAP1/027, which has 
been reported with severe outcomes in children.
46,47
 
 
4.8 Length of stay in hospital 
The median hospital length of stay (LOS) for pediatric SOT admissions with 
CDI was 7 days, which was 2 times longer than SOT admissions without CDI. The 
result is shorter than the LOS in adult SOT events with CDI, reported as —9 days in 
the Pant et al. study.72 We found that CDI was significantly associated with a longer 
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hospital LOS while controlling for other covariates in the gamma regression with log 
link analysis. The association might be, in part, due to the vulnerability to CDI 
triggered by hyogammaglobulinemia after organ. This may develop into severe CDI. 
If patients have shown symptoms of CDI, further laboratory tests to detect clostridium 
difficile may be required.62 Once a patient is diagnosed with CDI, medication 
treatment (e.g., 10-14 days for metronidazole or vancomycin) or surgery performance 
is essential.8 All of these factors—testing for clostridium difficile toxin, medication 
treatment, and surgery— may increase the number of days in the hospital. 
 
4.9 Hospital charges and costs 
The median hospital charges and costs for pediatric SOT events with CDI were 
$48,409 and $17,412, respectively. Both charges and costs for pediatric SOT 
admissions with CDI were 2 times higher than SOT admissions without CDI. We 
found that CDI was significantly associated with higher hospital charges and hospital 
costs while controlling for other covariates in the gamma regression with log link 
analysis. 
The median hospital charge was lower than the median hospital charge for adult 
SOT events with CDI—$53,808—reported by the Pant et al. study.72 The difference 
may be because adult SOT recipients have greater comorbid burdens. Specifically for 
adult SOT admissions with CDI, the majority had a CCI≧3 (66.6%)72 while the 
majority in our pediatric study had a CCI=0 (67.37%). When patients have more 
complex chronic comorbid conditions, this is likely to result in higher hospital 
charges and costs.  
A possible reason for charges and costs being significantly higher in pediatric 
SOT admissions with CDI than SOT admissions without CDI is because the immune 
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functions among patients who undergo SOT are weakened. Therefore, once CDI is 
diagnosed, these patients have a higher chance of developing severe CDI. They might 
need medication or even a colectomy for the treatment of CDI.8 These CDI treatments 
may increase the charges, costs, and LOS. Because children who undergo organ 
transplantation often suffer from complex diseases, medication for complex diseases 
they have already had, those follow-up expenditures after organ transplant— 
immunosuppressant, laboratory tests, etc—charges and costs might increase the total 
charges and costs substantially if patients have longer LOS. 
 
4.10 Limitations  
The following potential limitations should be considered while interpreting the 
results of this study: 
First, SOT patient selection was only based on ICD-9-CM diagnosis codes. 
Miscoding of ICD-9-CM codes may occur and lead to exclusion of those patients with 
relevant diagnoses. Also, disease severity could not be assessed from ICD-9-CM 
codes.  
Second, several covariates regarding comorbid conditions for solid organ 
transplant recipients, such as BK virus and Estein-Barr virus infections, were not 
available in this study due to the lack of specific ICD-9-CM codes. As for the 
comorbidity index, we used CCI in this study. Although CCI is commonly used to 
account for patient comorbidities, the sensitivity of the CCI in this study is unknown 
since CCI is not a specific comorbidity index for pediatric populations. 
Third, since we used a retrospective database, a number of covariates that may 
have explained partially significant variance in the dependent variables (e.g., prior use 
of antibiotics, laboratory values, and patient vitals) were not included in this study. 
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Fourth, the Kids’ Inpatient Database contains discharge-level rather than patient-
level data. This means readmissions cannot be identified—a patient with multiple 
hospitalizations in one year may have multiple records under different identifiers. 
Since we used discharge-level data, if one admission was due to a recurrence of CDI, 
the estimation of outcomes and expenditures remained unbiased, but the variances 
would become unstable.136 However, Kelsen et al. reported that the recurrence rate for 
CDI in hospitalized pediatric patients was 7.5%, which only accounts for a small 
portion in hospitalized pediatric patients with CDI.118 Therefore, although we used 
event-level data to capture the outcomes and expenditures of CDI in pediatric SOT 
recipients, the results may not be far from the results that would have been obtained if 
patient-level data were available. 
Finally, before conducting this study, we estimated our minimum total required 
sample sizes based on the data from adult populations. After conducting post-hoc 
analyses to calculate the actual power of our test, it was found that the power for some 
tests was relatively small.  
 
4.11 Strengths 
Since the KID was designed to collect data from US hospitalized pediatric 
populations, the samples represented our target population fairly well. Also, the 
dataset used for this study, the Kids’ Inpatient Database (KID), is a nationally 
representative database. Thus, the generalizability of this study was more expansive 
than studies using a database from a single institution or single population. 
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4.12 Conclusions and suggestions for future research 
The results of this study suggest that CDI is not significantly associated with 
higher hospital mortality and transplant failure or rejection. However, our results 
implicate CDI as a factor significantly related to a higher prevalence of colectomies, 
longer hospital LOS, higher charges, and higher costs. 
In general, health care providers need to be aware of risk factors for CDI in 
pediatric SOT recipients. Patients with diarrhea after organ transplantation should be 
evaluated carefully. In order to avoid substantially higher expenditures and health care 
utilization, CDI in pediatric SOT recipients should be promptly diagnosed and treated. 
Future research can use other data sources which include other important 
explanatory covariates (e.g., record of prior antibiotic use, laboratory data) and have 
more work on building and validating general comorbidity index for pediatric 
populations. Further investigation may focus on elucidating the factors that explain 
the difference of the association among outcomes, expenditures, and CDI between 
pediatric and adult populations. 
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